NZ617500B2 - Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists - Google Patents
Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists Download PDFInfo
- Publication number
- NZ617500B2 NZ617500B2 NZ617500A NZ61750012A NZ617500B2 NZ 617500 B2 NZ617500 B2 NZ 617500B2 NZ 617500 A NZ617500 A NZ 617500A NZ 61750012 A NZ61750012 A NZ 61750012A NZ 617500 B2 NZ617500 B2 NZ 617500B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- benzyl
- oxadiazolyl
- phenyl
- piperidinecarboxylic acid
- chloroisobutyl
- Prior art date
Links
- DNUTZBZXLPWRJG-UHFFFAOYSA-N piperidine-1-carboxylic acid Chemical class OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 title claims description 12
- 239000000018 receptor agonist Substances 0.000 title description 8
- -1 oxadiazole piperidine carboxylic acids Chemical class 0.000 claims abstract description 321
- 150000001875 compounds Chemical class 0.000 claims abstract description 147
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 206010012601 Diabetes mellitus Diseases 0.000 claims abstract description 6
- 206010027665 Immune disorder Diseases 0.000 claims abstract description 6
- 206010021425 Immune system disease Diseases 0.000 claims abstract description 6
- 208000006454 Hepatitis Diseases 0.000 claims abstract description 5
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 5
- YBRBMKDOPFTVDT-UHFFFAOYSA-N Tert-Butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 82
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 40
- 239000002253 acid Substances 0.000 claims description 35
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 34
- 239000011780 sodium chloride Substances 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 22
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 18
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
- 238000007792 addition Methods 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 9
- 206010052779 Transplant rejections Diseases 0.000 claims description 8
- 230000000875 corresponding Effects 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 159000000001 potassium salts Chemical class 0.000 claims description 7
- 210000001519 tissues Anatomy 0.000 claims description 7
- 206010003816 Autoimmune disease Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 201000001320 atherosclerosis Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 230000001590 oxidative Effects 0.000 claims description 5
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 4
- 208000006673 Asthma Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010061255 Ischaemia Diseases 0.000 claims description 4
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 4
- 208000003747 Lymphoid Leukemia Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010028154 Multi-organ failure Diseases 0.000 claims description 4
- 208000009525 Myocarditis Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 4
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 claims description 4
- 206010048908 Seasonal allergy Diseases 0.000 claims description 4
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 4
- 230000001684 chronic Effects 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 230000001771 impaired Effects 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 201000004681 psoriasis Diseases 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 206010006451 Bronchitis Diseases 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 208000007451 Chronic Bronchitis Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010018691 Granuloma Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 230000001808 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 230000001861 immunosuppresant Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 230000002757 inflammatory Effects 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 230000003612 virological Effects 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 229960002170 Azathioprine Drugs 0.000 claims description 2
- 108010007539 Blocking Antibodies Proteins 0.000 claims description 2
- 229940046731 Calcineurin inhibitors Drugs 0.000 claims description 2
- 229940119017 Cyclosporine Drugs 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 229940014456 MYCOPHENOLATE Drugs 0.000 claims description 2
- 229960000951 Mycophenolic Acid Drugs 0.000 claims description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 2
- 230000003213 activating Effects 0.000 claims description 2
- 230000001780 adrenocortical Effects 0.000 claims description 2
- 150000004791 alkyl magnesium halides Chemical class 0.000 claims description 2
- 108090001123 antibodies Proteins 0.000 claims description 2
- 102000004965 antibodies Human genes 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims description 2
- 230000000779 depleting Effects 0.000 claims description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- XOBKSJJDNFUZPF-UHFFFAOYSA-N methoxyethyl Chemical group CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 claims description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- ZBCRZEJNAADYKG-UHFFFAOYSA-N [4-methoxy-2-(trifluoromethyl)phenyl]boronic acid Chemical compound COC1=CC=C(B(O)O)C(C(F)(F)F)=C1 ZBCRZEJNAADYKG-UHFFFAOYSA-N 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 230000002194 synthesizing Effects 0.000 abstract description 3
- LVMPLKOXUWZFEN-UHFFFAOYSA-N 1-[[4-[5-(3-chloro-4-cyclohexylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-methylpiperidine-4-carboxylic acid Chemical compound C1CC(C)(C(O)=O)CCN1CC1=CC=C(C=2N=C(ON=2)C=2C=C(Cl)C(C3CCCCC3)=CC=2)C=C1 LVMPLKOXUWZFEN-UHFFFAOYSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 117
- 239000000243 solution Substances 0.000 description 82
- 239000011541 reaction mixture Substances 0.000 description 76
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- 230000002829 reduced Effects 0.000 description 53
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 35
- 239000000203 mixture Substances 0.000 description 34
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 34
- 239000002904 solvent Substances 0.000 description 33
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- 101710031679 HEXIM1 Proteins 0.000 description 31
- 102100014085 S1PR1 Human genes 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- 239000000460 chlorine Substances 0.000 description 30
- 238000004440 column chromatography Methods 0.000 description 29
- 229910052938 sodium sulfate Inorganic materials 0.000 description 29
- 235000011152 sodium sulphate Nutrition 0.000 description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 239000002585 base Substances 0.000 description 22
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- 125000004432 carbon atoms Chemical group C* 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 19
- 239000007864 aqueous solution Substances 0.000 description 17
- 239000000543 intermediate Substances 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- 101710037523 ACAT1 Proteins 0.000 description 16
- 102100014089 S1PR3 Human genes 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 238000003756 stirring Methods 0.000 description 14
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- 235000011121 sodium hydroxide Nutrition 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 230000035492 administration Effects 0.000 description 11
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 11
- 229960000583 Acetic Acid Drugs 0.000 description 10
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 10
- 206010025327 Lymphopenia Diseases 0.000 description 10
- 235000011054 acetic acid Nutrition 0.000 description 10
- 231100001023 lymphopenia Toxicity 0.000 description 10
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 101700071062 S1PR2 Proteins 0.000 description 8
- 102100014087 S1PR2 Human genes 0.000 description 8
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 8
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 8
- 210000004027 cells Anatomy 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000004494 ethyl ester group Chemical group 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 210000004072 Lung Anatomy 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- MYHJCTUTPIKNAT-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 MYHJCTUTPIKNAT-UHFFFAOYSA-N 0.000 description 5
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 5
- 101700000092 ANXA1 Proteins 0.000 description 5
- 210000004556 Brain Anatomy 0.000 description 5
- QOLCMRABVPXBRG-UHFFFAOYSA-N C(C1=CC=CC=C1)OCC1(CCN(CC1)C(=O)O)C(=O)O Chemical compound C(C1=CC=CC=C1)OCC1(CCN(CC1)C(=O)O)C(=O)O QOLCMRABVPXBRG-UHFFFAOYSA-N 0.000 description 5
- 210000002216 Heart Anatomy 0.000 description 5
- 102100014088 S1PR4 Human genes 0.000 description 5
- 230000002378 acidificating Effects 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229940043279 diisopropylamine Drugs 0.000 description 5
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 5
- 229960002994 dofetilide Drugs 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- AILZEXMVCHHZDU-UHFFFAOYSA-N ethyl 4-methylpiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(C)CC1 AILZEXMVCHHZDU-UHFFFAOYSA-N 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000001184 potassium carbonate Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N Hexamethylphosphoramide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- 210000003734 Kidney Anatomy 0.000 description 4
- 101700014909 NRG1 Proteins 0.000 description 4
- 102100014090 S1PR5 Human genes 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M Sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 210000000952 Spleen Anatomy 0.000 description 4
- 210000001541 Thymus Gland Anatomy 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000005842 heteroatoms Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- YHEDRJPUIRMZMP-ZWKOTPCHSA-N sphinganine 1-phosphate Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)COP(O)(O)=O YHEDRJPUIRMZMP-ZWKOTPCHSA-N 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-QYKNYGDISA-N 2-deuteriopyridine Chemical compound [2H]C1=CC=CC=N1 JUJWROOIHBZHMG-QYKNYGDISA-N 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- OHBZFZLYJFSASW-UHFFFAOYSA-N C1(CC1)CC1CCN(CC1)C(=O)O Chemical compound C1(CC1)CC1CCN(CC1)C(=O)O OHBZFZLYJFSASW-UHFFFAOYSA-N 0.000 description 3
- 210000000170 Cell Membrane Anatomy 0.000 description 3
- SBICHVALWFUYCE-UHFFFAOYSA-N ClC1(C(=CC=CC1)C1=CC=CC=C1)C(=O)O Chemical compound ClC1(C(=CC=CC1)C1=CC=CC=C1)C(=O)O SBICHVALWFUYCE-UHFFFAOYSA-N 0.000 description 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N Fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 3
- 210000004185 Liver Anatomy 0.000 description 3
- 210000004698 Lymphocytes Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000001058 adult Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000005879 dioxolanyl group Chemical group 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- YIDXEVJPPXFECF-UHFFFAOYSA-N ethyl 4-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(CO)CC1 YIDXEVJPPXFECF-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229960000556 fingolimod Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000001506 immunosuppresive Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000000329 lymphopenic Effects 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 108091008159 orphan GPCRs Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin dichloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- MSDQNIRGPBARGC-UHFFFAOYSA-N 1-(4-cyclohexylphenyl)ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1CCCCC1 MSDQNIRGPBARGC-UHFFFAOYSA-N 0.000 description 2
- BPGRMXNUHVYMRV-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]-4-(2-methylpropyl)piperidine-4-carboxylic acid Chemical compound CC(C)CC1(C(O)=O)CCN(C(=O)OC(C)(C)C)CC1 BPGRMXNUHVYMRV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N 2,3,4,5,6-pentadeuteriopyridine Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- IVDQHGMHSWHONB-UHFFFAOYSA-N 3-chloro-2-(2-methylpropyl)benzoic acid Chemical compound CC(C)CC1=C(Cl)C=CC=C1C(O)=O IVDQHGMHSWHONB-UHFFFAOYSA-N 0.000 description 2
- PZTNXMFVRCBRDR-UHFFFAOYSA-N 4-(2-methylpropyl)piperidine-1,4-dicarboxylic acid Chemical compound CC(C)CC1(C(O)=O)CCN(C(O)=O)CC1 PZTNXMFVRCBRDR-UHFFFAOYSA-N 0.000 description 2
- NLESZJUUVXZAAH-UHFFFAOYSA-N 4-bromo-2-chloro-1-phenylbenzene Chemical group ClC1=CC(Br)=CC=C1C1=CC=CC=C1 NLESZJUUVXZAAH-UHFFFAOYSA-N 0.000 description 2
- ZISGMPGRGVLFCN-UHFFFAOYSA-N 4-methylpiperidine-1,4-dicarboxylic acid Chemical compound OC(=O)C1(C)CCN(C(O)=O)CC1 ZISGMPGRGVLFCN-UHFFFAOYSA-N 0.000 description 2
- QFEVBIJRVDBXNE-UHFFFAOYSA-N 4-propylpiperidine-1,4-dicarboxylic acid Chemical compound CCCC1(C(O)=O)CCN(C(O)=O)CC1 QFEVBIJRVDBXNE-UHFFFAOYSA-N 0.000 description 2
- 210000000577 Adipose Tissue Anatomy 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K Aluminium chloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UMEDPTRTDYYSOG-UHFFFAOYSA-N BrCCCC1(CCN(CC1)C(=O)O)C(=O)O Chemical compound BrCCCC1(CCN(CC1)C(=O)O)C(=O)O UMEDPTRTDYYSOG-UHFFFAOYSA-N 0.000 description 2
- 208000006218 Bradycardia Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M Copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L Copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000036655 EDG receptors Human genes 0.000 description 2
- 108091007067 EDG receptors Proteins 0.000 description 2
- 102000003688 G-protein coupled receptors Human genes 0.000 description 2
- 108090000045 G-protein coupled receptors Proteins 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N Glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 229960001375 Lactose Drugs 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UJGFNNLDIQSDRH-UHFFFAOYSA-N OCC1(CCN(CC1)C(O)=O)C(O)=O Chemical compound OCC1(CCN(CC1)C(O)=O)C(O)=O UJGFNNLDIQSDRH-UHFFFAOYSA-N 0.000 description 2
- 210000004248 Oligodendroglia Anatomy 0.000 description 2
- VZJVWSHVAAUDKD-UHFFFAOYSA-N Potassium permanganate Chemical compound [K+].[O-][Mn](=O)(=O)=O VZJVWSHVAAUDKD-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N Pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- GLYOPNLBKCBTMI-UHFFFAOYSA-N [2-chloro-2-(1-chloro-2-phenylethoxy)ethyl]benzene Chemical compound C=1C=CC=CC=1CC(Cl)OC(Cl)CC1=CC=CC=C1 GLYOPNLBKCBTMI-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001483 arginine derivatives Chemical class 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229940045803 cuprous chloride Drugs 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N dilactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- MGASPGBUZVHQRD-UHFFFAOYSA-N ethyl 4-propylpiperidine-1-carboxylate Chemical compound CCCC1CCN(C(=O)OCC)CC1 MGASPGBUZVHQRD-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- YPPSVJYUVRPSMX-UHFFFAOYSA-N thiophen-2-ylmethyl methanesulfonate Chemical compound CS(=O)(=O)OCC1=CC=CS1 YPPSVJYUVRPSMX-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- XUXHXEMDOZHKDH-UHFFFAOYSA-N 1-(1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-1-ylmethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalene Chemical compound C1CCC2CCCCC2C1CC1C2CCCCC2CCC1 XUXHXEMDOZHKDH-UHFFFAOYSA-N 0.000 description 1
- QHUACTPKGSIZOO-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl 4-(hydroxymethyl)piperidine-1,4-dicarboxylate Chemical compound CCOC(=O)C1(CO)CCN(C(=O)OC(C)(C)C)CC1 QHUACTPKGSIZOO-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-Crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- YTDJTZGUTCBZCT-UHFFFAOYSA-N 2-aminobutanedioic acid;potassium Chemical compound [K].OC(=O)C(N)CC(O)=O YTDJTZGUTCBZCT-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- KDKJMZBICNRQQU-UHFFFAOYSA-N 3-chloro-4-(2-methylpropyl)benzoic acid Chemical compound CC(C)CC1=CC=C(C(O)=O)C=C1Cl KDKJMZBICNRQQU-UHFFFAOYSA-N 0.000 description 1
- WGHBJANAAQKWTJ-UHFFFAOYSA-N 3-chloro-4-cyclohexylbenzoic acid Chemical compound ClC1=CC(C(=O)O)=CC=C1C1CCCCC1 WGHBJANAAQKWTJ-UHFFFAOYSA-N 0.000 description 1
- LXPWGAZYJHUWPM-UHFFFAOYSA-N 4-(2-methylpropyl)benzaldehyde Chemical compound CC(C)CC1=CC=C(C=O)C=C1 LXPWGAZYJHUWPM-UHFFFAOYSA-N 0.000 description 1
- YATOYPVKSCZYBJ-UHFFFAOYSA-N 4-(cyclopropylmethyl)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(C(O)=O)CC1CC1 YATOYPVKSCZYBJ-UHFFFAOYSA-N 0.000 description 1
- LYJUVLFSCXZHSR-UHFFFAOYSA-N 4-(cyclopropylmethyl)piperidine-1,4-dicarboxylic acid Chemical compound C1CN(C(=O)O)CCC1(C(O)=O)CC1CC1 LYJUVLFSCXZHSR-UHFFFAOYSA-N 0.000 description 1
- UJGWLGLXDAUGLB-UHFFFAOYSA-N 4-bromo-N-chloroaniline Chemical compound ClNC1=CC=C(Br)C=C1 UJGWLGLXDAUGLB-UHFFFAOYSA-N 0.000 description 1
- CPPOXEDHAGNMET-UHFFFAOYSA-N 4-ethylpiperidine-1-carboxylic acid Chemical compound CCC1CCN(C(O)=O)CC1 CPPOXEDHAGNMET-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- JDZSSFNNZUQEOB-UHFFFAOYSA-N 4-propan-2-ylpiperidine-1-carboxylic acid Chemical compound CC(C)C1CCN(C(O)=O)CC1 JDZSSFNNZUQEOB-UHFFFAOYSA-N 0.000 description 1
- 230000035533 AUC Effects 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N Allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N Astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960004754 Astemizole Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 230000037242 Cmax Effects 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940009976 Deoxycholate Drugs 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 229950008932 Epolamine Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- QGWNDRXFNXRZMB-UUOKFMHZSA-N Guanosine diphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- APNSGVMLAYLYCT-UHFFFAOYSA-N Isobutyl nitrite Chemical compound CC(C)CON=O APNSGVMLAYLYCT-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 229940057948 Magnesium stearate Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229960003194 Meglumine Drugs 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GEIYENOTVUZLON-UHFFFAOYSA-N N1(CCCCC1)CCCC1(CCN(CC1)C(=O)O)C(=O)O Chemical compound N1(CCCCC1)CCCC1(CCN(CC1)C(=O)O)C(=O)O GEIYENOTVUZLON-UHFFFAOYSA-N 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- CXVCUMIJGGUUQB-UHFFFAOYSA-N OCCCC1(CCN(CC1)C(=O)O)C(=O)O Chemical compound OCCCC1(CCN(CC1)C(=O)O)C(=O)O CXVCUMIJGGUUQB-UHFFFAOYSA-N 0.000 description 1
- 230000035536 Oral bioavailability Effects 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 229940095574 Propionic acid Drugs 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- ZIKGVCXMZBAXLI-UHFFFAOYSA-N S1C(=CC=C1)CC1(CCN(CC1)C(=O)O)C(=O)O Chemical compound S1C(=CC=C1)CC1(CCN(CC1)C(=O)O)C(=O)O ZIKGVCXMZBAXLI-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M Sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229960005137 Succinic Acid Drugs 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N Sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 229940033134 Talc Drugs 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- HJUGFYREWKUQJT-UHFFFAOYSA-N Tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical group NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- HHNHBFLGXIUXCM-GFCCVEGCSA-N cyclohexylbenzene Chemical compound [CH]1CCCC[C@@H]1C1=CC=CC=C1 HHNHBFLGXIUXCM-GFCCVEGCSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- XZBSFDKGVZYHPW-UHFFFAOYSA-N ethyl 4-benzylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1CC1=CC=CC=C1 XZBSFDKGVZYHPW-UHFFFAOYSA-N 0.000 description 1
- ZALLFZWCIIZYGQ-UHFFFAOYSA-N ethyl 4-ethylpiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(CC)CC1 ZALLFZWCIIZYGQ-UHFFFAOYSA-N 0.000 description 1
- MNZCAZZZUZYHKB-UHFFFAOYSA-N ethyl 4-phenylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1C1=CC=CC=C1 MNZCAZZZUZYHKB-UHFFFAOYSA-N 0.000 description 1
- ROYXOEDYIVTQDH-UHFFFAOYSA-N ethyl 4-prop-2-enylpiperidine-4-carboxylate Chemical compound CCOC(=O)C1(CC=C)CCNCC1 ROYXOEDYIVTQDH-UHFFFAOYSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- YSPVHAUJXLGZHP-UHFFFAOYSA-N ethyl piperidine-1-carboxylate Chemical compound CCOC(=O)N1CCCCC1 YSPVHAUJXLGZHP-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002140 halogenating Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000043 immunodepressive Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulators Drugs 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- AXLIQWDXMFMDMT-UHFFFAOYSA-N lithium;carbanide;lithium Chemical compound [Li].[Li+].[CH3-] AXLIQWDXMFMDMT-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000036220 oral bioavailability Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001991 pathophysiological Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000004437 phosphorous atoms Chemical group 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- IIKFXOLJMNWWCH-UHFFFAOYSA-N piperidine-1,4-dicarboxylic acid Chemical compound OC(=O)C1CCN(C(O)=O)CC1 IIKFXOLJMNWWCH-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OCFVSFVLVRNXFJ-UHFFFAOYSA-N potassium hydride Inorganic materials [H-].[K+] OCFVSFVLVRNXFJ-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- HBDYSKVKXMUPKV-UHFFFAOYSA-N pyridine;trioxochromium;hydrochloride Chemical compound [H+].[Cl-].O=[Cr](=O)=O.C1=CC=NC=C1 HBDYSKVKXMUPKV-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical class OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 235000020071 rectified spirit Nutrition 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 229940013123 stannous chloride Drugs 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- ZPHGMBGIFODUMF-UHFFFAOYSA-N thiophen-2-ylmethanol Chemical compound OCC1=CC=CS1 ZPHGMBGIFODUMF-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Disclosed herein are the compounds of formula I which are oxadiazole piperidine carboxylic acids where the subsituents are as defined herein, an example being 1-{4-[5-(3-chloro-4-cyclohexylphenyl)-[1,2,4]-oxadiazol-3-yl]benzyl}-4-methylpiperidine-4-carboxylic acid. Also disclosed are methods of synthesis of these compounds and their use in conditions such as immune disorders, diabetes, hepatitis and cancer. hesis of these compounds and their use in conditions such as immune disorders, diabetes, hepatitis and cancer.
Description
NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS
The present invention relates to novel compounds acting as agonists at S1P
(sphingosinephosphate) receptors, compositions containing these compounds, use of
these compounds in medicine and their process of preparation.
S1P is a bioactive sphingolipid metabolite that is intimately involved in mediating
various immunological processes by its actions on S1P receptors. S1P receptor, originally
termed as endothelial differentiation gene (EDG) receptor, is a family of five related G-protein
coupled receptors, namely S1P1/EDG1, S1P2/EDG5, S1P3/EDG3, S1P4/EDG6 and
S1P5/EDG8. These receptors have wide spread cellular and tissue distribution and are well
conserved in human and rodent species.
S1P is stored and released from platelets upon their activation, but can also be
synthesized in a wide variety of cell types in response to extracellular stimuli like growth
factors and cytokines. It is involved in a number of cellular functions including cell growth,
differentiation, migration and apoptosis and thus may have an important role in
pathophysiological disease states such as atherosclerosis and cancer. S1P exerts these
diverse cellular effects depending on the expression of the specific S1P receptors subtypes
and its coupling to these receptors.
EDG1 receptor was the first identified S1P receptor that was initially isolated as an
orphan GPCR (G protein-coupled receptor) in human endothelial cells, and it was later
shown to encode a high-affinity S1P receptor. Expression of EDG1 is pervasive, including
spleen, brain, heart, lung, adipose tissues, liver, thymus, kidney, and skeletal muscle. EDG5
was first isolated as an orphan GPCR gene from rat cardiovascular and nervous systems. Its
expression is widespread; it is present in heart, lung, thymus, brain, liver, kidney, spleen,
adipose tissues in adult mouse, and in lung, heart, stomach, intestine, and adrenal glands in
rats. EDG3 was isolated as an orphan GPCR gene by degenerate PCR-based cloning from a
human genomic DNA library. Like EDG5, EDG3 is a high-affinity S1P receptor. The
expression of EDG3 is widespread; it is present in the spleen, heart, lung, thymus, kidney,
testis, brain, and skeletal muscle in adult mice and, in humans, in the heart, placenta, kidney,
liver, pancreas, skeletal muscle, lung, and brain. Unlike EDG1, EDG5 and EDG3 receptors,
EDG6 expression is restricted in human and mouse to lymph node, spleen, lung, and
thymus. This expression pattern suggests potential roles of EDG6 in the immune system. In
vivo roles and functions of EDG6 are still unknown. In rat brain, EDG8 is predominantly
expressed in white matter tracts and cells of oligodendrocyte lineage, suggesting its potential
roles in maturation and myelination of oligodendrocytes. The physiological roles for EDG8
have not been found in the published literature.
EDG1 receptor mediated responses play an essential role in modulating cell
trafficking between the lymphatic system and blood. EDG1 receptor agonists cause
sequestration of lymphocytes in secondary lymphoid organs which is associated with
clinically useful immunosuppression. Immunosuppression is desirable to prevent and/or treat
rejection after organ, tissue or cell transplantation and in the treatment of autoimmune
disorders. Agents acting as immunosuppressants have been shown to be useful in a variety
of autoimmune and inflammatory disorders like transplant rejection, tissue graft rejection,
immune disorders, auto immune disorders, autoimmune uveitis, ischemia, rheumatoid
arthritis, pollinosis, multiple sclerosis, sepsis, inflammatory bowel disease, asthma, diabetes
mellitus, atherosclerosis, lupus erythematosus, myocarditis, multiorgan failure,
glomerulonephritis, atopic dermatitis, lymphocytic leukemias, lymphomas, Alzheimer’s
disease, pneumonia, psoriasis as well as disorders related to impaired vascular integrity,
cancers, disregulated angiogenesis or excessive neoangiogenesis.
Recently, FTY720 (Fingolimod), an EDG1 receptor agonist has been approved by
FDA for treatment of patients with relapsing form of Multiple Sclerosis. However, there are
certain studies which report FTY720 to have an adverse effect of asymptomatic bradycardia,
which is reported to be due to nonselective agonism at the EDG3 receptor (Bioorg. &Med.
Chem. Lett., 2004, 14, 3501)
Thus, there is a continued interest in developing S1P receptor agonists showing
receptor selectivity at EDG1 receptor, specifically, compounds which show low relative
activity at EDG3 receptor expressed in cardiac tissues. (Hale et al, Bioorg. Med. Chem. Lett.
14, (2004), 3501-3505). Various EDG1 agonists have been disclosed in prior art references.
For example WO2003105771 assigned to Merck discloses EDG1 agonists, which were
oxadiazole compounds substituted by aryl group at the 3- and 5-positions. All the compounds
disclosed in this application were either azetidinyl- or pyrrolidinyl carboxylic acids.
WO2007132307, assigned to Pfizer, discloses EDG1 receptor agonist compounds having
oxadiazole ring substituted at 3- and 5- position by aryl group. All the compounds disclosed in
this application were aminocycloalkyl carboxylic acids, more specifically aminocyclobutanes
substituted by carboxylic acid group. WO2008152149 relates to dicarboxylic acids as EDG1
agonists.
The present invention relates to certain novel piperidine monocarboxylic acids which
are effective as agonists on human S1P1 receptors. The present invention relates to a
compound of formula (I):
COOH
wherein:
Ar is an aryl group optionally substituted by one or more identical or different group(s)
selected from halogen, alkyl, cycloalkyl, -Oalkyl, aryl wherein the alkyl, cycloalkyl, -Oalkyl,
aryl may be further substituted with halogen, OH, Oalkyl, CN, NH , NHalkyl, Nalkyl , alkyl;
R1 represents –X-(Y)n
where
-X- is selected from –alkyl-, -alkenyl-, -alkynyl-, -aryl-, -alkylaryl-,
Each Y, identical or different is selected from H, OH, halogen, -Oalkyl, -Oalkylaryl,
-OalkylOalkyl, -Oaryl, heteroaryl, -Oaryl(Oalkyl), -Ocycloalkyl, -cycloalkyl, heterocyclyl;
n is 1 to 3;
R2 is selected from H, alkyl;
or one of its stereoisomers, salts or esters thereof.
In a preferred embodiment, the present invention relates to the compound of formula
(I), wherein Ar is a Phenyl group, more preferably Ar is a disubstituted Phenyl wherein the
substituents are as defined above for formula (I).
The invention also provides a process of preparation of a compound of the invention
comprising saponifying a compound of formula (III)
N R2
COOAlk
(III)
where Ar, R2, R1 are as defined above and Alk represents a C1-C6 alkyl group, optionally
followed by forming the desired addition salt.
The invention also provides a process of preparation of a compound of the invention
comprising reacting a compound of formula (VII):
N R2
(VII)
with a compound of formula (VIII)
COOR
(VIII)
where Ar, R2, R1 are as defined above, and R may be alkyl, optionally followed by forming
the desired addition salt.
The invention also provides a compound prepared by the process of the invention.
Unless specified otherwise, the terms used hereabove or hereafter have the meaning
ascribed to them below:
“Halo”, “hal” or “halogen” refers to fluorine, chlorine, bromine or iodine atom.
"Alkyl'' represents an aliphatic-hydrocarbon group which may be straight or branched
having 1 to 20 carbon atoms in the chain unless specified otherwise. Preferred alkyl groups
have 1 to 12 carbon atoms, more preferably have 1 to 8 carbon atoms in the chain, most
preferably have 1 to 6 carbon atoms in the chain. In a particularly preferred embodiment the
alkyl group has 1 to 4 carbon atoms in the chain. Exemplary alkyl groups include methyl,
ethyl, n-propyl, iso-propyl, iso-butyl, n-butyl, tert-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl.
"Cycloalkyl" refers to a non-aromatic mono- or polycyclic hydrocarbon ring system of
3 to 10 carbon atoms. More preferably the cycloalkyl group has of 4 to 10 carbon atoms,
more preferably 4 to 8 carbon atoms and most preferably have 4 to 6 carbon atoms.
Exemplary monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, and the like. Exemplary multicyclic cycloalkyl include 1-decalin, norbornyl,
adamant-(1- or 2-)yl.
"Aryl" refers to an aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring system of
6 to 14 carbon atoms. More preferably aryl refers to a nonocyclic or bicyclic ring containing 6
to 10 carbon atoms. Exemplary aryl groups include phenyl, naphthyl, indenyl, phenanthryl,
biphenyl. Most preferably the aryl group is Phenyl.
"Alkenyl" refers to an aliphatic hydrocarbon group containing a carbon-carbon double
bond and which may be straight or branched having 2 to 15 carbon atoms in the chain unless
specified otherwise. Preferred alkenyl groups have 2 to 12 carbon atoms in the chain; more
preferably about 2 to 8 carbon atoms in the chain and most preferably have 2 to 4 carbon
atoms in the chain. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, iso-
butenyl, 3-methylbutenyl, n-pentenyl, heptenyl, octenyl, nonenyl, decenyl.
"Alkynyl" refers to an aliphatic hydrocarbon group containing a carbon-carbon triple
bond and which may be straight or branched having 2 to 15 carbon atoms in the chain unless
specified otherwise. Preferred alkynyl groups have 2 to 12 carbon atoms in the chain; more
preferably have 2 to 8 carbon atoms in the chain, most preferably have 2 to 4 carbon atoms
in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl,
3-methylbutynyl, n-pentynyl, 4,4-dimethylpentynyl, heptynyl, octynyl and decynyl.
“Arylalkyl” refers to an alkyl group substituted with an aryl group. The terms “alkyl”
and “aryl” are as defined above.
“-Oarylalkyl” refers to a group wherein –O is attached to an alkyl group which is
substituted with an aryl group. The terms “alkyl” and “aryl” are as defined above. Exemplary
“Oarylalkyl” groups include –O-CH -Phenyl.
The term "heteroaryl" refers to a 5 to 14, preferably 5 to 10 membered aromatic
mono-, bi- or multicyclic ring wherein at least one member of the ring is a hetero atom such
as N, O, S. Examples include pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl,
tetrazolyl, indolyl, quinolinyl, purinyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl,
benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazoyl, tetrazolyl, isoquinolyl, benzothienyl,
isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl.
The terms "heterocycle", “heterocyclyl” or "heterocyclic" refer to a saturated or
partially unsaturated non aromatic stable 3 to 14, preferably 5 to 10-membered mono, bi or
multicyclic rings wherein at least one member of the ring is a hetero atom, such as N, O, S.
Typically, heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, selenium, and
phosphorus atoms. Preferable heteroatoms are oxygen, nitrogen and sulfur. Suitable
heterocycles are also disclosed in the Handbook of Chemistry and Physics, 76th Edition,
CRC Press, Inc., 1995-1996, pages 2-25 to 2-26, the disclosure of which is hereby
incorporated by reference. Preferred non aromatic heterocyclic include, but are not limited to
oxetanyl, tetraydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidyl,
morpholinyl, imidazolidinyl, pyranyl. Preferred saturated heterocycles are chosen from
tetrahydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidyl, morpholinyl,
imidazolidinyl, more preferably tetrahydrofuranyl, dioxolanyl, tetrahydropyranyl.
"Alkyl", "cycloalkyl", "alkenyl", "alkynyl", "aryl", etc… also refers to the corresponding
divalent "alkylene", "cycloalkylene", "alkenylene", "alkynylene", "arylene", etc., which are
formed by the removal of two hydrogen atoms.
The compounds of the present invention possess an acidic group and a basic group
which may form corresponding salts. Thus the present invention includes salts of compounds
of formula (I). The salts may preferably be pharmaceutically acceptable salts. The acidic
group may form salts with bases. The base may be an organic amine base, for example
trimethylamine, tert-butylamine, tromethamine, meglumine, epolamine, etc. The acidic group
may also form salts with inorganic bases like sodium hydroxide, potassium hydroxide, etc.
The basic group may form salts with inorganic acids like hydrochloric acid, sulfuric acid,
hydrobromic acid, sulfamic acid, phosphoric acid, nitric acid etc and organic acids like acetic
acid, propionic acid, succinic acid, tartaric acid, citric acid, methanesulfonic acid,
benzenesulfonic acid, glucoronic acid, glutamic acid, benzoic acid, salicylic acid,
toluenesulfonic acid, oxalic acid, fumaric acid, maleic acid etc. Further, compounds of
formula (I) may form quaternary ammonium salts and salts with amino acids such as
arginine, lysine, etc. Lists of suitable salts may be found in Remington's Pharmaceutical
Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418 and P.H. Stahl,
C.G. Wermuth, Handbook of Pharmaceutical salts - Properties, Selection and Use, Wiley-
VCH, 2002, the disclosures of which are hereby incorporated by reference.
As used herein, the term "patient" refers to a warm-blooded animal such as a
mammal, preferably a human or a human child, which is afflicted with, or has the potential to
be afflicted with one or more diseases and conditions described herein.
As used herein, a "therapeutically effective amount" refers to an amount of a
compound of the present invention which is effective in reducing, eliminating, treating or
controlling the symptoms of the herein-described diseases and conditions. The term
"controlling" is intended to refer to all processes wherein there may be a slowing, interrupting,
arresting, or stopping of the progression of the diseases and conditions described herein, but
does not necessarily indicate a total elimination of all disease and condition symptoms, and is
intended to include prophylactic treatment and chronic use.
As used herein, the expression "pharmaceutically acceptable" refers to those
compounds, materials, compositions, or dosage forms which are, within the scope of sound
medical judgment, suitable for contact with the tissues of human beings and animals without
excessive toxicity, irritation, allergic response, or other problem complications commensurate
with a reasonable benefit/risk ratio.
The term “comprising” as used in this specification means “consisting at least in part
of”. When interpreting each statement in this specification that includes the term
“comprising”, features other than that or those prefaced by the term may also be present.
Related terms such as “comprise” and “comprises” are to be interpreted in the same manner.
A preferred embodiment of compound of formula (I) is described herein and
represented by a compound of formula (II):
COOH
(II)
or one of its isomers, salts or esters thereof
wherein:
R1 is selected as in formula (I); and/or
R3 is selected from halogen, C alkyl , C cycloalkyl, -O-C alkyl, aryl; More preferably R3
1-6 3-7 1-6
is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, secondary butyl, tertiary
butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, cyclopentyl, cyclohexyl, cycloheptyl, isopropoxy,
phenyl. Most preferably R3 is selected from phenyl, cyclohexyl, cyclopentyl, isobutyl;and/or
Hal represents a halogen, such as F, Cl, Br, I.
Also described is compound of formula (II) wherein R1 is selected from C alkyl, C
1-6 2-4
alkenyl, C alkynyl, aryl and arylalkyl each being optionally substituted by one or more of
OH, halogen, -Oalkyl, -Oarylalkyl, -OalkylOalkyl, Oaryl, heteroaryl, -Oaryl(Oalkyl), -
Ocycloalkyl, -cycloalkyl, heterocyclyl.
More preferably R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, secondary butyl, tertiary butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, hydroxymethyl,
hydroxyethyl, hydroxypropyl, methoxymethyl, ethoxymethyl, methoxyethyl, vinyl, allyl,
methoxyethoxymethyl, ethoxyethoxymethyl, ethoxyethoxyethyl, Phenyl, benzyl,
benzyloxymethyl, benzyloxyethyl, -CH-[Ph(o-F)], -CH-[Ph(m-F)], -CH-[Ph(p-F)], -CH -
2 2 2 2
[Ph(o-OMe)], -CH -[Ph(m-OMe)], -CH -[Ph(p-OMe)], methoxybutyl, methoxyethoxymethyl, -
CH -[Ph(o,o-F)], -CH -[Ph(m-CF)], -CH-furyl, -CH-pyridyl, (2-methoxy-phenoxy)-ethyl,
2 2 2 3 2 2
4-methoxy-benzyl, isopropoxymethyl, cyclopentyloxymethyl, thiophenylmethyl,
cyclopropylmethyl, 2-morpholinyl-ethyl, 3-piperidinyl-propyl, 3-pyrrolidinyl-propyl.
Still more preferably, R1 is selected from methyl, ethyl, n-propyl, hydroxymethyl,
methoxymethyl, allyl, methoxyethoxymethyl, Phenyl, benzyl, benzyloxymethyl, -CH -[Ph(o-
F)], -CH-[Ph(p-F)], -CH-[Ph(o-OMe)], -CH-[Ph(p-OMe)], methoxybutyl,
2 2 2
methoxyethoxymethyl, -CH -[Ph(o,o-F)], -CH -[Ph(m-CF)], -CH-furyl, -CH-pyridyl, (2-
2 2 2 3 2 2
methoxy-phenoxy)-ethyl, 4-methoxy-benzyl, isopropoxymethyl, cyclopentyloxymethyl,
thiophenylmethyl, cyclopropylmethyl, 2-morpholinyl-ethyl, 3-piperidinyl-propyl, 3-
pyrrolidinyl-propyl.
wherein, p-F, o-F, p-OMe and o-OMe stands for para-fluoro, ortho-fluoro, para-
methoxy and ortho-methoxy respectively.
More preferably, described is a compound of formula (I) or (II) above, wherein:
R1 is selected from –CH , -C H , -n-C H , -CH -O-CH , -CH -CH=CH , -CH -O-CH -
3 2 5 3 7 2 3 2 2 2 2
CH -OCH, -Ph, -CH -O-CH-Ph, -CH-Ph, -CH-[Ph(p-F)], -CH-[Ph(o-F)], -CH -[Ph(p-
2 3 2 2 2 2 2 2
OMe)], -CH-[Ph(o-OMe)] or -CHOH, methoxybutyl, methoxyethoxymethyl,
methoxyethoxyethyl, -CH -CH -O-Ph, -CH(CH ) , -CH -[Ph(o,o-F )], -CH -[Ph(m-CF )], -CH -
2 2 3 2 2 2 2 3 2
furyl, -CH-pyridyl, (2-methoxy-phenoxy)-ethyl, 4-methoxy-benzyl, isopropoxymethyl,
cyclopentyloxymethyl, thiophenylmethyl, cyclopropylmethyl, 2-morpholinyl-ethyl, 3-
piperidinyl-propyl, 3-pyrrolidinyl-propyl. ; and/or
- R3 is selected from phenyl, cyclohexyl, cyclopentyl, isobutyl, isopropoxy;
wherein, p-F, o-F, p-OMe and o-OMe stands for para-fluoro, ortho-fluoro, para-methoxy and
ortho-methoxy respectively.
Also described is a compound of formula (I) or (II) wherein when R1 is –CH , -C H , -
3 2 5
n-C H , -CH -O-CH , -CH -CH=CH , -CH -O-CH -CH -OCH , -Ph, -CH -O-CH -Ph, -CH -Ph,
3 7 2 3 2 2 2 2 2 3 2 2 2
-CH-[Ph(p-F)], -CH-[Ph(o-F)], -CH-[Ph(p-OMe)], -CH-[Ph(o-OMe)], -CH OH,
2 2 2 2 2
methoxybutyl, methoxyethoxymethyl, methoxyethoxyethyl, isopropoxymethyl, -CH -CH -O-
Ph, -CH(CH ) -CH -[Ph(o,o-F )], -CH -[Ph(m-CF )], -CH -furyl, -CH -pyridyl, (2-methoxy-
3 2 2 2 2 3 2 2
phenoxy)-ethyl, 4-methoxy-benzyl, isopropoxymethyl, cyclopentyloxymethyl, thiophen
ylmethyl, cyclopropylmethyl, 2-morpholinyl-ethyl, 3-piperidinyl-propyl, 3-pyrrolidinyl-
propyl,
then R3 is isobutyl;
when R1 is –CH , -C H , -n-C H , -CH -O-CH , -CH -CH=CH , -CH -O-CH -CH -OCH ,
3 2 5 3 7 2 3 2 2 2 2 2 3
-CH -O-CH -Ph, , -CH -pyridyl,, CH -[Ph(OMe)], -CH -[Ph(F)], -CH -Ph or -CH OH then R3 is
2 2 2 2 2 2 2
–Ph;
when R1 is –CH , – CH CH , -CH -O-CH CH -[Ph(OMe)], then R3 is –cyclohexyl;
3 2 3 2 3 , 2
when R1 is –CH or -CH -O-CH then R3 is cyclopentyl;
3 2 3
when R1 is –CH -CH , -CH -CH=CH -CH -O-CH3 or -CH -O-CH -CH -O-CH then R3 is
2 3 2 2 , 2 2 2 2 3
isopropoxy.
Following are examples of some of the representative compounds described herein.
These examples are for illustration purposes only and should not be considered to be limiting
the invention.
1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine
carboxylic acid
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine
carboxylic acid
1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine
carboxylic acid
1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidinecarboxylic
acid
1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methoxymethylpiperidinecarboxylic acid
1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methoxymethylpiperidinecarboxylic acid
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}ethylpiperidine
carboxylic acid
4-allyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}piperidinecarboxylic
acid
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}propylpiperidine
carboxylic acid
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2-
methoxyethoxymethyl)piperidinecarboxylic acid
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}hydroxymethylpiperidine-
4-carboxylic acid
1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]oxadiazolyl]-benzyl}methoxymethylpiperidine-
4-carboxylic acid
4-Allyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidinecarboxylic
acid
1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}propylpiperidinecarboxylic
acid
1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-
methoxyethoxymethyl)piperidinecarboxylic acid
4-Benzyloxymethyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidine
carboxylic acid
4-Benzyloxymethyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-
benzyl}piperidinecarboxylic acid
1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}hydroxymethylpiperidine
carboxylic acid
1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}phenylpiperidine
carboxylic acid
4-Benzyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}-piperidine
carboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(4-fluoro-benzyl)-piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(2-fluoro-benzyl)-piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(4-methoxy-benzyl)-piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(2-methoxy-benzyl)-piperidinecarboxylic acid
1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methoxymethylpiperidine
carboxylic acid
1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}ethylpiperidinecarboxylic
acid
1-{4-[5-(4-Isobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidinecarboxylic
acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-butyl)-
piperidinecarboxylic acid
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2-
methoxyethoxymethyl)piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-phenoxy-ethyl)-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2,6-difluoro-benzyl)-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isobutyl-piperidine
carboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropyl-piperidine
carboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(3-trifluoro methyl-
benzyl)-piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}furanylmethyl-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}[2-(2-methoxy-phenoxy)-
ethyl]-piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine
carboxylic acid
1-{4-[5-(4-tert-Butylchloro-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine
carboxylic acid
1-{4-[5-(3-Chloropropyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine
carboxylic acid
1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-methoxy-
ethoxymethyl)-piperidinecarboxylic acid
1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl-piperidine
carboxylic acid
4-Allyl{4-[5-(3-chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine
carboxylic acid
1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-piperidine-
4-carboxylic acid
1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)-
piperidinecarboxylic acid
1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-fluoro-benzyl)-piperidine-
4-carboxylic acid
1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)-
piperidinecarboxylic acid
1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl-piperidine
carboxylic acid
4-Benzyl{4-[5-(2-chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine
carboxylic acid
1-{4-[5-(3-Chlorocyclohexyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methoxymethyl-
piperidinecarboxylic acid
1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-piperidine-
4-carboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-ethoxy-ethoxymethyl)-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropoxy methyl-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}cyclopentyloxymethyl-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}thiophenylmethyl-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}cyclopropylmethyl-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-morpholinyl-ethyl)-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3-piperidinyl-propyl)-
piperidinecarboxylic acid
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3-pyrrolidinyl-propyl)-
piperidinecarboxylic acid
or one of their isomers, salts or esters thereof.
Also described are compounds including the following:
1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine
carboxylic acid
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine
carboxylic acid, tert-butylamine salt
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine
carboxylic acid
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine
carboxylic acid, sodium salt
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine
carboxylic acid, arginine salt
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine
carboxylic acid, potassium salt
1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine
carboxylic acid
1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidinecarboxylic
acid
1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methoxymethylpiperidinecarboxylic acid, tert-butylamine salt
1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methoxymethylpiperidinecarboxylic acid tert-butylamine salt
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}ethylpiperidine
carboxylic acid tert-butylamine salt
4-allyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}piperidinecarboxylic
acidtert-butylamine salt
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}propylpiperidine
carboxylic acid tert-butylamine salt
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2-
methoxyethoxymethyl)piperidinecarboxylic acid tert-butylamine salt
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}hydroxymethylpiperidine-
4-carboxylic acid tert-butylamine salt
1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]oxadiazolyl]-benzyl}methoxymethylpiperidine-
4-carboxylic acid tert-butylamine salt
4-Allyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidinecarboxylic
acid tert-butylamine salt
1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}propylpiperidinecarboxylic
acid tert-butylamine salt
1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-
methoxyethoxymethyl)piperidinecarboxylic acid tert-butylamine salt
4-Benzyloxymethyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidine
carboxylic acid tert-butylamine salt
4-Benzyloxymethyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-
benzyl}piperidinecarboxylic acid tert-butylamine salt
1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}hydroxymethylpiperidine
carboxylic acid tert-butylamine salt
1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}phenylpiperidine
carboxylic acid tert-butylamine salt
4-Benzyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}-piperidine
carboxylic acid tert-butylamine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(4-fluoro-benzyl)-piperidinecarboxylic acid tert-butylamine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(2-fluoro-benzyl)-piperidinecarboxylic acid tert-butylamine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(4-methoxy-benzyl)-piperidinecarboxylic acid tert-butylamine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(2-methoxy-benzyl)-piperidinecarboxylic acid tert-butylamine salt
1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methoxymethylpiperidine
carboxylic acid tert-butylamine salt
1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}ethylpiperidinecarboxylic
acid tert-butylamine salt
1-{4-[5-(4-Isobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidinecarboxylic
acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-butyl)-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2-
methoxyethoxymethyl)piperidinecarboxylic acid potassium salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-phenoxy-ethyl)-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2,6-difluoro-benzyl)-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isobutyl-piperidine
carboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropyl-piperidine
carboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(3-trifluoro methyl-
benzyl)-piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}furanylmethyl-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}[2-(2-methoxy-phenoxy)-
ethyl]-piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine
carboxylic acid tert-butyl amine salt
1-{4-[5-(4-tert-Butylchloro-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine
carboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloropropyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine
carboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-methoxy-
ethoxymethyl)-piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl-piperidine
carboxylic acid tert-butyl amine salt
4-Allyl{4-[5-(3-chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine
carboxylic acid tert-butyl amine salt
1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-piperidine-
4-carboxylic acid tert-butyl amine salt
1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-fluoro-benzyl)-piperidine-
4-carboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl-piperidine
carboxylic acid tert-butyl amine salt
4-Benzyl{4-[5-(2-chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine
carboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chlorocyclohexyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methoxymethyl-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-piperidine-
4-carboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-ethoxy-ethoxymethyl)-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropoxy methyl-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}cyclopentyloxymethyl-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}thiophenylmethyl-
piperidinecarboxylic acid tert-butyl amine salt
1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}cyclopropylmethyl-
piperidinecarboxylic acid tert-butyl amine salt
or one of their isomers.
Also described is the process of preparation of the compound of formula (I).
The compounds and process described herein may be prepared in a number of ways
well known to those skilled in the art. The compounds can be synthesized, for example, by
application or adaptation of the methods described below, or variations thereon as
appreciated by the skilled artisan. The appropriate modifications and substitutions will be
readily apparent and well known or readily obtainable from the scientific literature to those
skilled in the art.
In particular, such methods can be found in R.C. Larock, Comprehensive Organic
Transformations, VCH publishers, 1989
It will be appreciated that the compounds described herein may contain one or more
asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic
forms. Thus, all chiral, diastereomeric, racemic forms and all geometric isomeric forms of a
structure are intended, unless the specific stereochemistry or isomeric form is specifically
indicated. It is well known in the art how to prepare and isolate such optically active forms.
For example, mixtures of stereoisomers may be separated by standard techniques including,
but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral
chromatography, preferential salt formation, recrystallization, and the like, or by chiral
synthesis either from chiral starting materials or by deliberate synthesis of target chiral
centers.
Compounds described herein may be prepared by a variety of synthetic routes. The
reagents and starting materials are commercially available, or readily synthesized by well-
known techniques by one of ordinary skill in the arts. All substituents, unless otherwise
indicated, are as previously defined.
In the reactions described hereinafter, it may be necessary to protect reactive
functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these
are desired in the final product, to avoid their unwanted participation in the reactions.
Conventional protecting groups may be used in accordance with standard practice, for
examples see T.W. Greene and P. G. M. Wuts in Protective Groups in Organic Synthesis,
John Wiley and Sons, 1991; J. F. W. McOmie in Protective Groups in Organic Chemistry,
Plenum Press, 1973.
Some reactions may be carried out in the presence of a base. There is no particular
restriction on the nature of the base to be used in this reaction, and any base conventionally
used in reactions of this type may equally be used here, provided that it has no adverse
effect on other parts of the molecule. Examples of suitable bases include: sodium hydroxide,
potassium carbonate, triethylamine, alkali metal hydrides, such as sodium hydride and
potassium hydride; alkyllithium compounds, such as methyllithium and butyllithium; and alkali
metal alkoxides, such as sodium methoxide and sodium ethoxide.
Usually, reactions are carried out in a suitable solvent. A variety of solvents may be
used, provided that it has no adverse effect on the reaction or on the reagents involved.
Examples of suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or
cycloaliphatic hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene;
amides, such as dimethyl-formamide; alcohols such as ethanol and methanol and ethers,
such as diethyl ether and tetrahydrofuran.
The reactions can take place over a wide range of temperatures. In general, we find it
convenient to carry out the reaction at a temperature of from 0°C to 150°C (more preferably
from about room temperature to 100°C). The time required for the reaction may also vary
widely, depending on many factors, notably the reaction temperature and the nature of the
reagents. However, provided that the reaction is effected under the preferred conditions
outlined above, a period of from 3 hours to 20 hours will usually suffice.
The compound thus prepared may be recovered from the reaction mixture by
conventional means. For example, the compounds may be recovered by distilling off the
solvent from the reaction mixture or, if necessary after distilling off the solvent from the
reaction mixture, pouring the residue into water followed by extraction with a water-immiscible
organic solvent and distilling off the solvent from the extract. Additionally, the product can, if
desired, be further purified by various well-known techniques, such as recrystallization,
reprecipitation or the various chromatography techniques, notably column chromatography or
preparative thin layer chromatography.
In particular, the compounds described herein may be prepared from the processes
described below. The intermediates used in the processes are either commercially available
or may be synthesized in the laboratory from well-known starting materials and processes.
The process of preparing the compounds of the present invention is apparent or readily
obtainable from prior art references, eg. WO2003/105771, WO2008152149
According to a first embodiment, the process of preparation of a compound of formula
(I) comprises saponifying a compound of formula (III):
N R2
COOAlk
(III)
where Ar, R2, R1 are defined as in formula (I) and Alk represents an alkyl group, optionally
followed by forming the desired addition salt.
The saponification reaction is generally conducted in the presence of a mineral base
such as NaOH, KOH or their mixtures, preferably at a temperature comprised between the
room temperature and the reflux temperature of the reaction mixture.
The addition salt is generally obtained by reacting the formed acid with a base
corresponding to the desired addition salt. The added base can be organic including amines,
such as tert-butylamine, or inorganic bases such as NaOH, KOH, etc.
Following addition of the base, the compound of formula (I) is generally in the form of
the carboxylate salt, where the counter ion is the cation resulting from the addition of a proton
to the base.
The acid form of the compound of formula (I) may be recovered from its base addition
salt by acidifying said salt.
The compound of formula (III) may be obtained by coupling a compound of formula
(IV):
(IV)
with a corresponding compound of formula (V):
COOAlk
where Ar, R2, R1 are defined as in formula (I), Alk is defined as in formula (III) and LG is a
leaving group such as a halogen atom, preferably Cl or the mesylate (O-SO2-CH3) group.
This reaction is generally conducted in the presence of a base. Where LG is a
halogen atom, the base may be potassium carbonate to neutralize the formed acid.
When LG is mesylate the base may be organic, preferably N,N-diisopropylethylamine,
triethyl amine or inorganic, preferably potassium, cesium or sodium carbonate.
Preferably, the reaction is conducted at a temperature comprised between the room
temperature and the reflux temperature of the reaction mixture.
The compound of formula (IV) wherein LG is a halide or mesylate may be obtained by
converting a compound of formula (VI):
N R2
(VI)
where Ar and R2 are defined as in formula (I) into the desired halide or mesylate.
The substitution reaction may be conducted by reacting said compound of formula
(VI) with usual halogenating agents such as thionyl halogenide, hydrohalogenide acid H-Hal,
phosphorus trihalogenide, etc., preferably thionyl chloride. Alternatively, the mesylate
derivative may be obtained by reacting said compound (VI) with mesyl chloride, in the
presence of a base such as a tertiary amine, in particular triethylamine or an inorganic base,
such as carbonate, hydrogenocarbonate.
According to a second embodiment, the compound of formula (I) may be obtained by
reacting a compound of formula (VII):
N R2
(VII)
with a compound of formula (VIII):
COOR
(VIII)
where Ar, R2, R1 are defined as in formula (I) and R may be H or alkyl, optionally followed by
forming the desired addition salt.
This reaction is generally carried out in acidic medium (such as in the presence of
acetic acid), followed by the addition of a reductive agent such as sodium cyanoborohydride.
If a base addition salt of the compound of formula (I) is desired, this reaction may be
followed by the addition of a base, as discussed above.
The compound of formula (VII) may be obtained by oxidizing a compound of formula
(VI):
(VI)
where Ar and R2 are defined as in formula (I). This reaction may be carried out in known
conditions generally used for oxidizing primary or secondary alcohol, as the case may be. In
particular, this reaction may be conducted in the presence of pyridinium chlorochromate
(PCC).
The compound of formula (VI) used in both embodiments above may be obtained by
(a) reacting a compound of formula (IX):
(IX)
where Ar is defined as in formula (I)
with N-hydroxyhydroxymethylbenzamidine, optionally in the presence of one or more of
activating and/or coupling agent, such as N,N’-Dicyclohexylcarbodiimide (DCC) and
N-hydroxybenzotriazole monohydrate (HOBt), so as to form a compound of formula (VI)
where R2 is H, and optionally followed when a compound (VI) where R2 is alkyl is desired by
(b) oxidizing the compound of formula (VI) (wherein R2 is H) followed by its reaction with
alkylmagnesiumhalide.
The process described herein may also include the additional step of isolating the
obtained compounds.
The compounds of formula (IX), (VII), (VIII), (V) and N-hydroxy
hydroxymethylbenzamidine are commercially available or may be synthesized by applying or
adapting known procedures.
The compounds of formula (VI):
N R2
(VI)
wherein Ar and R2 are defined as in formula (II), where R2 is selected from H, alkyl and Ar
represents a group of formula:
wherein Hal represents a Cl atom and R3 is selected from halogen, aryl, cycloalkyl, alkyl are
novel and are another object of the present disclosure.
In particular, in formula (X) R3 is selected from cycloalkyl such as cyclohexyl or
cyclopentyl; alkyl such as iso-butyl; or aryl such as phenyl.
The salts of described herein can be synthesized from the parent compound which
contains a basic or acidic moiety by conventional chemical methods. Generally, such salts
can be prepared by reacting the free acid or base forms of these compounds with a
stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in
a mixture of the two and such methods are within the level of a skilled person.
Also described are the isomers of the compounds of formula (I). The isomers can be
prepared by separation of the corresponding racemic compounds by methods well known in
the art.
Also described are esters of compound of formula (I). These may be prepared by
methods well known to a person of skill in the art. For example, the esters may be prepared
by the reaction of an acid with alcohol of the desired ester. For example, the compounds of
formula (I) with a –COOH group may be reacted with methanol to form methyl ester of
compound of formula (I). Similarly, ethyl, propyl, isobutyl and other esters can be prepared
The compounds described herein may be useful for the treatment and/or prevention
of conditions associated with S1P1/EDG1 receptor or where decrease in lymphocytes
circulating in blood is desired, which include immune mediated diseases and conditions or
inflammatory diseases and conditions.
The compounds described herein are suitable as immunosuppressive/
immunodepressive agents. These compounds are suitable for the treatment and/or
prevention of transplant rejection, tissue graft rejection, immune disorders auto-immune
diseases, autoimmune uveitis, ischemia, inflammatory and chronic inflammatory conditions
that include rheumatoid arthritis, asthma, pollinosis, psoriasis, Alzheimer’s disease,
myocarditis, atopic dermatitis, lymphocytic leukemias, lymphomas, sepsis, multiple sclerosis,
lupus erythematosus, inflammatory bowel diseases, diabetes mellitus, glomerulonephritis,
atherosclerosis, multiorgan failure, pneumonia, ischemia reperfusion injury, chronic
obstructive pulmonary disease, infection associated with inflammation, viral inflammation,
hepatitis, chronic bronchitis, granulomatous disease, as well as disorders related to impaired
vascular integrity, cancer, or other disorders. The compounds of the present invention are
generally selective EDG1 receptor agonists with very low affinity for EDG3 receptor. The
selective agonism of EDG1 over EDG3 is desirable in view of the bradycardia caused by the
nonselective agonism at EDG3 receptor. Also the compounds of the inventioin have low
affinity for hERG channel due to which they exhibit a better side effect profile.
The compounds described herein may be used in combination with other
immunomodulators or immunosuppressants including adrenocortical steroids, cyclosporine,
azathioprine, methotrexate, calcineurin inhibitors, IL-2 receptor blocking antibodies, T-cell
depleting antibodies, anti-TNF, mycophenolate, mTOR inhibitors. Said combinations are
another object of the present invention.
A typical dose range for use according to the present disclosure may be from 1 µg/kg
to 0.1 g/kg of body weight per day; a preferred dose range may be from 3 µg/kg to 1 mg/kg
of body weight per day. The most potent compounds could even be administered only two to
three times per week at typical dosages of 10 to 100 µg/kg. Daily dose for adult humans
includes 0.1 to 10 mg which can be optimized.
The dosage of drug to be administered depends on such variables as the type and
extent of progression of the disease or disorder, the overall health status of the particular
patient, the relative biological efficacy of the compound selected, and formulation of the
compound, excipients , and its route of administration.
The compounds described herein may be formulated into a pharmaceutically
acceptable preparation, on admixing with a carrier, excipient or a diluent, in particular for oral
or parenteral use. Certain preferred compounds display good oral bioavailability and are thus
well suited for preparing formulations for oral use. Such preparations may be in the form of
tablets, capsules or parenterals. A solid carrier can include one or more substances which
may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants,
compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating
material. Liquid carriers can include water, an organic solvent, a mixture of both or
pharmaceutically acceptable oils and fats. The compositions may conveniently be
administered in unit dosage form and may be prepared by any of the methods well known in
the pharmaceutical art, for example, as described in Remington: The Science and Practice of
Pharmacy, 20th ed.; Gennaro, A . R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA,
2000. Pharmaceutically compatible binding agents and/or adjuvant materials can be included
as part of the composition.
The tablets, pills, powders, capsules, troches and the like can contain one or more of
any of the following ingredients, or compounds of a similar nature: a binder such as
microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a
disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium
stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or
saccharin; or a flavoring agent such as peppermint, or methyl salicylate. Capsules can be in
the form of a hard capsule or soft capsule, which are generally made from gelatin blends
optionally blended with plasticizers, as well as a starch capsule. In addition, dosage unit
forms can contain various other materials that modify the physical form of the dosage unit,
for example, coatings of sugar, shellac, or enteric agents. Other oral dosage forms syrup or
elixir may contain sweetening agents, preservatives, dyes, colorings, and flavorings. In
addition, the active compounds may be incorporated into fast dissolve, modified-release or
sustained-release preparations and formulations, and wherein such sustained-release
formulations are preferably bi-modal.
Preferred formulations include pharmaceutical compositions in which a compound
described herein is formulated for oral or parenteral administration, or more preferably those
in which a compound of the present invention is formulated as a tablet. Preferred tablets
contain lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone,
magnesium stearate, or talc in any combination. It is also an aspect of the present disclosure
that a compound of the present invention may be incorporated into a food product or a liquid.
Liquid preparations for administration include sterile aqueous or non-aqueous solutions,
suspensions, and emulsions. The liquid compositions may also include binders, buffers,
preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like. Non-
aqueous solvents include alcohols, propylene glycol, polyethylene glycol, acrylate
copolymers, vegetable oils such as olive oil, and organic esters such as ethyl oleate.
Aqueous carriers include mixtures of alcohols and water, hydrogels, buffered media, and
saline. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide
copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to
control the release of the active compounds. Intravenous vehicles can include fluid and
nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and
the like. Other potentially useful parenteral delivery systems for these active compounds
include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion
systems, and liposomes.
Alternative modes of administration include formulations for inhalation, which include
such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for
example, polyoxyethylenelauryl ether, glycocholate and deoxycholate, or oily solutions for
administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations
for buccal administration include, for example, lozenges or pastilles and may also include a
flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
Formulations suitable for rectal administration are preferably presented as unit-dose
suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.
Formulations for topical application to the skin preferably take the form of an ointment,
cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which can be used include petroleum
jelly, lanolin, polyethylene glycols, alcohols, or their combinations. Formulations suitable for
transdermal administration can be presented as discrete patches and can be lipophilic
emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an
adhesive.
Alternative administrations include also solutions, ointments or other formulations
acceptable for ocular administration.
According to a particular aspect, the compound described herein may be administered
by the cutaneous, ocular or inhalation route as disclosed above. These formulations are
particularly advantageous as they ensure a local treatment, without associated lymphopenia
which may occur with systemic administration routes.
Other features of the invention will become apparent in the course of the following
description of exemplary embodiments that are given for illustration of the invention and not
intended to be limiting thereof.
The above mentioned features of the invention are given for illustration of the
invention and not intended to be limiting thereof.
Preparation of intermediates
I) Preparation of 3-chlorocyclohexylbenzoic acid
Step (a)
Anhydrous aluminium chloride (1.65 g, 0.012 mol) is added to a solution of cyclohexyl
benzene (1 g, 0.006 mol) and acetyl chloride (0.7 mL, 0.009 mol) in dichloroethane (10 mL)
at -5°C to 0°C temperature. The reaction mixture is stirred at this temperature for 30 minutes
and then treated with 2N hydrochloric acid (7 mL). It is extracted with dichloromethane (2x20
mL) and the combined extract is dried over sodium sulfate. After removing the solvent under
reduced pressure the residue is purified by column chromatography (silica gel, 230-400
mesh, ethyl acetate:n-hexane 7:93) to get 1-(4-cyclohexylphenyl)ethanone.
Step (b)
A mixture of concentrated sulfuric acid & nitric acid (68-72%) (1.7:6, 15 mL) is added
drop wise to a cold solution of 1-(4-cyclohexylphenyl)ethanone (6 g, 0.03 mol) in
concentrated sulfuric acid (15 mL) at 0-5°C. Reaction mixture is allowed to stir at this
temperature for 30 minutes & is then poured into crushed ice. It is then extracted with ethyl
acetate (3x40 mL). Combined organic layer is dried over sodium sulfate and concentrated
under reduced pressure. The residue is purified by column chromatography (silica gel, 230-
400 mesh, ethyl acetate:n-hexane 1:9) to yield 1-(4-cyclohexylnitrophenyl)ethanone.
Step (c)
NO NH
Stannous chloride dihydrate (15.8 g, 0.07 mol) is added to a solution of 1-(4-
cyclohexylnitrophenyl)ethanone (5.8 g , 0.0235 mol) in concentrated hydrochloric acid (35
mL) at 0-5°C. The reaction mixture is slowly brought to 60-65°C and is stirred at this
temperature for 15 minutes. After cooling to room temperature the reaction mixture is
extracted with ethyl acetate (3x100 mL). The pH is adjusted to 8.0 - 9.0 using solid sodium
bicarbonate. After washing with water (1x15 mL) the organic layer is dried over sodium
sulfate and concentrated under reduced pressure to yield the crude, which is purified by
column chromatography (230-400 mesh; ethyl acetate:n-hexane, 3:7) to give 1-(3-amino
cyclohexylphenyl)ethanone.
Step (d)
NH Cl
Solution of sodium nitrite (1.2 g, 0.017 mol) in demineralized water (7 mL) is added to
a solution of 1-(3-aminocyclohexylphenyl)ethanone (3.4 g, 0.016 mol) in concentrated
hydrochloric acid (34 mL) at 0-5°C & is allowed to stir for 15 minutes at this temperature. It is
then poured into a slurry of cuprous chloride (3.1 g, 0.03 mol) in demineralized water (10 mL)
at 60-65°C & stirred for 30 minutes. The reaction mixture is extracted in ethyl acetate (2x30
mL). Combined organic layer is dried over sodium sulfate and concentrated to get the crude,
which is purified using column chromatography (230-400 mesh; toluene:n-hexane, 3:2) to
yield 1-(3-chlorocyclohexyl-phenyl)ethanone.
Step (e)
Cl Cl
An aqueous alkaline solution of potassium permanganate (2.94 g, 0.0186 mol; in
22 mL 12% aqueous sodium hydroxide) is added to solution of 1-(3-chloro
cyclohexylphenyl)ethanone (2.2 g, 0.0093 mol) in dioxane (11 mL). The reaction mixture is
stirred at 80°C temperature for 2 hrs. It is then filtered and the filtrate is washed with diethyl
ether (2x10 mL). The pH of the aqueous layer is adjusted to1-2 by using 6N hydrochloric
acid. It is extracted in ethyl acetate (3x15 mL). Combined organic layer is dried over sodium
sulfate and concentrated to get the crude, which is purified using column chromatography
(230-400 mesh; ethyl acetate:n-hexane, 1:3) to yield 3-chlorocyclohexyl benzoic acid.
II) Preparation of 3-chlorocyclopentylbenzoic acid
This compound is prepared in the same way as mentioned for 3-chlorocyclohexyl
benzoic acid (I).
III) Preparation of 3-chloroisobutylbenzoic acid
Step (a)
4-Isobutyl benzaldehyde (7 g, 0.0431 mol) is added drop wise to a mixture of
concentrated sulfuric acid & nitric acid (68-72%) (9:1, 60 mL) at 0-5°C. Reaction mixture is
allowed to stir at this temperature for 2 hrs, then poured into crushed ice. It is then extracted
with ethyl acetate (3x40 mL). Combined organic layer is dried over sodium sulfate and
concentrated under reduced pressure. The residue is purified by column chromatography
(silica gel, 230-400 mesh, ethyl acetate:n-hexane 1:19) to yield 4-isobutyl
nitrobenzaldehyde.
Step (b)
NO Cl
4-Isobutylnitrobenzaldehyde (3.3 g, 0.0159 mol) is added to a solution of stannous
chloride (8.37 g, 0.0441 mol) in concentrated hydrochloric acid (23 mL) at 0-5°C. The
reaction mixture is slowly brought to 60-65 C and is stirred at this temperature for 30 minutes.
The reaction mixture is again cooled to 0-5°C. During cooling formation of solid is observed
which is broken before proceeding further. Solution of sodium nitrite (1.36 g, 0.0188 mol) in
demineralized water (3 mL) is added to the above reaction mixture at 0-5 C, allowed to stir
for 10 minutes at this temperature. It is then poured into a slurry of cuprous chloride (3.6 g,
0.0346 mol) in demineralized water (5 mL) at 60-65 C & stirred for 20 minutes. The reaction
mixture is extracted in ethyl acetate (2x30 mL). Combined organic layer is dried over sodium
sulfate and concentrated to get the crude, which is purified using column chromatography
(230-400 mesh; toluene:n-hexane, 3:7) to yield 3-chloroisobutylbenzaldehyde.
Step (c)
Cl Cl
A mixture of sodium chlorite (80% assay, 1.06 g, 0.0094 mol) and sodium
dihydrogenphosphate dihydrate (3.33 g, 0.0213 mol) in demineralized water (10 mL) is added
in two equal lots (one hr interval) to a solution of 3-chloroisobutylbenzaldehyde (0.7 g,
0.0036 mol) in tert-butanol (10 mL) at room temperature. After completion of addition, stirring
at room temperature is continued for 4 hrs. It is then extracted in ethyl acetate (2x30 mL).
Combined organic layer is dried over sodium sulfate and concentrated under reduced
pressure to give 3-chloroisobutylbenzoic acid.
IV) Preparation of 2-chlorobiphenylcarboxylic acid
Step (a)
Isobutyl nitrite (121 g, 1.17 mol) and cupric chloride (21.2 g, 0.16 mol) are added to a
solution of 4-bromochloroaniline (200 g, 0.97 mol) in benzene (500 mL) at 60-65 C
temperature. The reaction mixture is refluxed for 2 hrs. The reaction mixture is cooled to 50-
55 C temperature and to it a solution of aqueous sulfuric acid (92 mL conc. Sulfuric acid in
453 mL demineralized water). After refluxing for 1 hr the reaction mixture is cooled to room
temperature and organic layer is separated. It is treated with an aqueous solution of urea
(41g in 127 mL water) and refluxed for 1 hr. Organic layer is separated, washed with
demineralized water (2x200 mL) and dried over sodium sulfate. After removing the solvent
under reduced pressure the residue is fractionally distilled to get 4-bromochlorobiphenyl.
Step (b)
Few crystals of iodine are added to tetrahydrofuran (200 mL) containing magnesium
turnings (2.8 g, 0.117 mol). The mixture is heated at 60-70C. A solution of 4-bromo
chlorobiphenyl (26 g, 0.097 mol) in tetrahydrofuran (50 mL) is added dropwise to the reaction
mixture and refluxed for 1hr. Reaction mixture is brought to room temperature and then
cooled to -20°C. Carbon dioxide gas is passed through the reaction mixture for 45 minutes.
The reaction mixture is treated with 3N HCl (125 mL) and extracted with ethyl acetate
(2x200 mL). Combined organic layer is dried over sodium sulphate. Removal of solvent
under reduced pressure gives a solid which is washed with diethyl ether (2x100 mL) and then
dried to furnish 2-chlorobiphenylcarboxylic acid.
V) Preparation of 4-methylpiperidinecarboxylic acid ethyl ester
Step (a)
n-Butyllithium (15% solution in n-hexane; 82 mL, 0.19 mol) is added to a stirred
solution of diisopropyl amine (28.75 mL, 0.20 mol ) in tetrahydrofuran (400 mL) at -70°C
under an atmosphere of nitrogen and stirred for 30 minutes. A solution of piperidine-1,4-
dicarboxylic acidtert-butyl ester 4-ethyl ester (30 g, 0.12 mol) in tetrahydrofuran (80 mL) is
introduced at -70°C. Hexamethyl phosphoramide (45 mL) is added and reaction mixture is
allowed to stir till the temperature reaches at -45°C. Reaction mixture again cooled to -70°C,
methyl iodide (39.3 mL, 0.60 mol) is added and stirred for 1 hour. Saturated aqueous solution
of ammonium chloride (100 mL) is added slowly into the reaction mixture at 0°C and stirred
for 10 minutes. It is extracted with ethyl acetate (3x200 mL). Combined organic layer is
washed with brine solution (1x100 mL) and dried over sodium sulfate. Removal of solvent
under reduced pressure gives a viscous liquid which is purified by column chromatography
(silica gel 230-400, n-hexane:ethyl acetate, 9:1) to furnish 4-methyl piperidine-1,4-
dicarboxylic acidtert-butylesterethyl ester.
Step (b)
O HN
A solution of hydrochloric acid (12N, 12.5 mL) in dioxane (25 mL) is added to 4-methyl
piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester (7.5 g, 0.028 mol) and stirred
at room temperature for 1 hr. The reaction mixture is concentrated under reduced pressure
and the residue is treated with aqueous solution of sodium bicarbonate to adjust the pH to 8 -
9. It is again concentrated under reduced pressure and the residue is treated with
dichloromethane. After drying over sodium sulfate solvent is removed to get the crude
residue which is purified by column chromatography (silica gel 230-400 mesh,
methanol:dichloromethane:ammonium hydroxide 14:85:1) to get 4-methylpiperidine
carboxylic acid ethyl ester.
Following compounds, VI to XIV (except IX), can be prepared by following a process
similar to compound V.
VI) 4-Ethylpiperidinecarboxylic acid ethyl ester
VII) 4-(2-Methoxyethoxymethyl)piperidinecarboxylic acid ethyl ester
VIII) 4-Methoxymethylpiperidinecarboxylic acid ethyl ester
IX) 4-Phenyl-piperidinecarboxylic acid ethyl ester
This material is commercially available.
X) 4-Benzyl-piperidinecarboxylic acid ethyl ester
XI) 4-(4-Fluoro-benzyl)-piperidinecarboxylic acid ethyl ester
XII) 4-(2-Fluoro-benzyl)-piperidinecarboxylic acid ethyl ester
XIII) 4-(4-Methoxy-benzyl)-piperidinecarboxylic acid ethyl ester
XIV) 4-(2-Methoxy-benzyl)-piperidinecarboxylic acid ethyl ester
XV) Preparation of 4-allylpiperidinecarboxylic acid ethyl ester
Step (a)
n-Butyllithium (15% solution in n-hexane; 24.5 mL, 0.057 mol) is added to a stirred
solution of diisopropyl amine (8.38 mL, 0.059 mol ) in tetrahydrofuran (140 mL) at -70°C
under an atmosphere of nitrogen and stirred for 30 minutes. A solution of piperidine-1,4-
dicarboxylic acidtert-butyl esterethyl ester (8.0 g, 0.0311 mol) in tetrahydrofuran (20
mL) is introduced at -70°C. Hexamethyl phosphoramide (15 mL) is added and reaction
mixture is allowed to stir till the temperature reaches at -45°C. Reaction mixture again cooled
to -70°C, allyl bromide (13.5 mL, 0.155 mol) is added and stirred for 1 hour. Saturated
aqueous solution of ammonium chloride (100 mL) is added slowly into the reaction mixture at
-30°C and stirred for 10 minutes. It is extracted with ethyl acetate (3x60 mL).Combined
organic layer is washed with brine solution (1x30 mL) and dried over sodium sulfate.
Removal of solvent under reduced pressure gives a viscous liquid which is purified by column
chromatography (silica gel 230-400, n-hexane:ethyl acetate, 9:1) to furnish 4-allyl piperidine-
1,4-dicarboxylic acidtert- butylesterethyl ester.
Step (b)
O HN
A solution of hydrochloric acid (12N, 4 mL) in dioxane (6 mL) is added to 4-allyl
piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester (2 g, 0.006 mol) and stirred at
room temperature for 30 minutes. The reaction mixture is concentrated under reduced
pressure and the residue is treated with aqueous solution of sodium bicarbonate to adjust the
pH to 8 - 9. It is again concentrated under reduced pressure and the residue is treated with
dichloromethane. After drying over sodium sulfate solvent is removed to get 4-allylpiperidine-
4-carboxylic acid ethyl ester.
XVI) Preparation of 4-propylpiperidinecarboxylic acid ethyl ester
Step (a)
O N O N
% Pd/C (0.6 g, 50% wet) is added to a stirred solution of 4-allylpiperidine-1,4-
dicarboxylicacidtert-butylesterethyl ester (2.1 g, 0.007 mol) in ethanol (20 mL).
Hydrogen gas is bubbled through the reaction mixture at room temperature for 20 minutes.
Reaction mixture is filtered through celite bed and washed with methanol (3x5 mL).
Combined filtrate is concentrated under reduced pressure to give 4-propylpiperidine-1,4-
dicarboxylic acidtert-butyl ester- 4-ethyl ester.
Step (b)
O HN
A solution of hydrochloric acid (12N, 4.2 mL) in dioxane (6.8 mL) is added to 4-
propylpiperidine-1,4-dicarboxylic acidtert-butyl ester- 4-ethyl ester (2.2 g, 0.0073 mol) and
stirred at room temperature for 30 minutes. The reaction mixture is concentrated under
reduced pressure and the residue is treated with aqueous solution of sodium bicarbonate to
adjust the pH to 8 - 9. It is again concentrated under reduced pressure and the residue is
treated with dichloromethane. After drying over sodium sulfate solvent is removed to get 4-
propylpiperidinecarboxylic acid ethyl ester.
XVII) Preparation of 4-benzyloxymethyl-piperidinecarboxylic acid ethyl ester
Step (a)
n-Butyllithium (15% solution in n-hexane; 9.5 mL, 0.022 mol) is added to a stirred
solution of diisopropyl amine (3.1 mL, 0.022 mol ) in tetrahydrofuran (15 mL) at -70°C under
an atmosphere of nitrogen and stirred for 30 minutes. A solution of piperidine-1,4-dicarboxylic
acidtert butyl esterethyl ester (3 g, 0.012 mol) in tetrahydrofuran (10 mL) is introduced
at -70°C. Hexamethyl phosphoramide (4.8 mL) is added and reaction mixture is allowed to
stir till the temperature reaches at -45°C. Reaction mixture again cooled to -70°C, benzyl
chloromethyl ether (5 mL, 0.035 mol) is added and stirred for 1 hour. Saturated aqueous
solution of ammonium chloride (30 mL) is added slowly into the reaction mixture at -30°C and
stirred for 10 minutes. It is extracted with ethyl acetate (2x20 mL). Combined organic layer is
dried over sodium sulfate. Removal of solvent under reduced pressure gives a viscous liquid
which is purified by column chromatography (silica gel 230-400, toluene:ethyl acetate, 23:2 to
furnish 4-benzyloxymethylpiperidine-1,4-dicarboxylic acidtert butyl esterethyl ester.
Step (b)
A solution of hydrochloric acid (12N, 1.5 mL) in dioxane (7.5 mL) is added to 4-
benzyloxymethylpiperidine-1,4-dicarboxylic acidtert butyl esterethyl ester (1.9 g, 0.005
mol) and stirred at room temperature for 30 minutes. The reaction mixture is concentrated
under reduced pressure and the residue is treated with aqueous solution of sodium
bicarbonate to adjust the pH to 8 - 9. It is again concentrated under reduced pressure and
the residue is treated with dichloromethane. After drying over sodium sulfate solvent is
removed to get 4-benzyloxymethylpiperidinecarboxylic acid ethyl ester.
XVIII) Preparation of 4-hydroxymethylpiperidinecarboxylic acid ethyl ester
Step (a)
n-Butyllithium (15% solution in n-hexane; 9.5 mL, 0.022 mol) is added to a stirred
solution of diisopropyl amine (3.1 mL, 0.022 mol ) in tetrahydrofuran (15 mL) at -70°C under
an atmosphere of nitrogen and stirred for 30 minutes. A solution of piperidine-1,4-dicarboxylic
acidtert-butyl esterethyl ester (3 g, 0.012 mol) in tetrahydrofuran (10 mL) is introduced
at -70°C. Hexamethyl phosphoramide (4.8 mL) is added and reaction mixture is allowed to
stir till the temperature reaches at -45°C. Reaction mixture again cooled to -70°C, benzyl
chloromethyl ether (5 mL, 0.035 mol) is added and stirred for 1 hour. Saturated aqueous
solution of ammonium chloride (30 mL) is added slowly into the reaction mixture at -30°C and
stirred for 10 minutes. It is extracted with ethyl acetate (2x20 mL). Combined organic layer is
dried over sodium sulfate. Removal of solvent under reduced pressure gives a viscous liquid
which is purified by column chromatography (silica gel 230-400, toluene:ethyl acetate, 23:2 to
furnish 4-benzyloxymethylpiperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester.
Step (b)
% Pd/C (1.85 g, 50% wet) is added to a solution of 4-benzyloxymethylpiperidine-1,4-
dicarboxylic acidtert-butyl ester ethyl ester (1.85 g, 0.0049 m0l) in ethanol (20 mL). The
reaction mixture is stirred under the positive pressure of hydrogen gas for 16 hrs at room
temperature. The reaction mixture is filtered through celite bed and washed with a solution
methanol and dichloromethane (1:5, 100 mL). Combine filtrate is concentrated under
reduced pressure to give 4-hydroxymethylpiperidine-1,4-dicarboxylic acid 1-tert- butyl ester-
4-ethyl ester.
Step (c)
O HN
A solution of hydrochloric acid (12N, 2.5 mL) in dioxane (4.5 mL) is added to 4-
hydroxymethylpiperidine-1,4-dicarboxylic acidtert- butyl esterethyl ester (1.35 g, 0.0047
mol) and stirred at room temperature for 30 minutes. The reaction mixture is concentrated
under reduced pressure and the residue is treated with aqueous solution of sodium
bicarbonate to adjust the pH to 8 - 9. It is again concentrated under reduced pressure and
the residue is treated with dichloromethane. After drying over sodium sulfate solvent is
removed to get 4-hydroxymethylpiperidinecarboxylic acid ethyl ester.
Following intermediates XIX to XXIX can be prepared following the same procedure
as that of intermediate V
XIX) 4-(4-Methoxy-butyl)-piperidinecarboxylic acid ethyl ester
XX) 4-(2-Phenoxy-ethyl)-piperidinecarboxylic acid ethyl ester
XXI) 4-(2,6-Difluoro-benzyl)-piperidinecarboxylic acid ethyl ester
XXII) 4-Pyridinylmethyl-piperidinecarboxylic acid ethyl ester
XXIII) 4-[2-(2-Methoxy-phenoxy)-ethyl]-piperidinecarboxylic acid ethyl ester
XXIV) 4-(4-Methyl-benzyl)-piperidinecarboxylic acid ethyl ester
XXV) 4-Pyridinylmethyl-piperidinecarboxylic acid ethyl ester
XXVI) 4-Pyridinylmethyl-piperidinecarboxylic acid ethyl ester
XXVII) 4-Isopropoxymethyl-piperidinecarboxylic acid ethyl ester
XXVIII) 4-Cyclopentyloxymethyl-piperidinecarboxylic acid ethyl ester
XXIX) 4-(2-Morpholinyl-ethyl)-piperidinecarboxylic acid ethyl ester
XXX) 4-Isobutylpiperidinecarboxylic acid
Step (a)
This compound is prepared by following a process same as that of 4-
methylpiperidine-1,4-dicarboxylic acid tert-butyl esterethyl ester [step (a) of intermediate
Step (b)
% Pd/C (0.3 g, 50% wet) is added to a solution of 4-(2-methylallyl)piperidine-1,4-
dicarboxylic acidtert-butyl esterethyl ester (1.0 g, 0.0032 mol) in ethanol (10 mL). The
reaction mixture is stirred under the positive pressure of hydrogen gas for 1 hr at room
temperature. The reaction mixture is filtered through celite bed and washed with ethanol (15
mL). Combine filtrate is concentrated under reduced pressure to get 4-isobutylpiperidine-1,4-
dicarboxylic acidtert-butyl esterethyl ester.
Step (c)
A solution of potassium hydroxide (85% assay, 2.69 g, 0.041 mol) and sodium
hydroxide (1.94 g, 0.048 mol) in demineralized water (8 mL) is added to a solution of 4-
isobutylpiperidine-1,4-dicarboxylic acidtertbutyl esterethyl ester (0.95 g, 0.003 mol) in
ethanol (15 mL). The reaction mixture is refluxed for 48 hrs. It is cooled to room temperature,
concentrated under reduced pressure, and then treated with demineralized water (10 mL).
The pH is adjusted to ~ 3-4 using 2N HCl (10 mL) and the aqueous layer is extracted with
ethyl acetate (2x15 mL). The combined extract is dried over sodium sulfate. Removal of
solvent gives a crude residue which is purified by column chromatography (230-400 mesh,
ethyl acetate:n-hexane 1:3) to furnish 4-isobutylpiperidine-1,4-dicarboxylic acid monotertbutyl
ester.
Step (d)
A solution of hydrochloric acid (12N, 1.2 mL) in 1,4-dioxane (2.4 mL) is added to 4-
isobutylpiperidine-1,4-dicarboxylic acid monotertbutyl ester (0.7 g, 0.0025 mol) and stirred at
room temperature for 1 hr. The reaction mixture is concentrated under reduced pressure and
the residue is treated with saturated solution of sodium bicarbonate (0.5 mL) to adjust the pH
to ~ 7. It is again concentrate under reduced pressure to get crude 4-isobutylpiperidine
carboxylic acid.
XXXI) 4-Cyclopropylmethyl-piperidinecarboxylic acid
Step (a)
O O N
This compound is prepared following the same procedure as that of 4-
methylpiperidine-1,4-dicarboxylic acid tert-butyl esterethyl ester [step (a) of intermediate
Step (b)
Potassium hydroxide powder (85% assay, 2.16 gm, 0.0327 mol) and 18-crown-6
ether (350 mg) are added to a solution of 4-cyclopropylmethylpiperidine-1,4-dicarboxylic acid-
1-tertbutyl esterethyl ester (1.2 gm, 0.0039 mol) in dry toluene (15 mL). The reaction
mixture is refluxed for 30 minutes. It is then treated with demineralized water (15 mL) at room
temperature and pH is adjusted to ~ 3- 4 using 2N HCl (20 mL). The aqueous layer is
extracted with ethyl acetate (2x15 mL) and the combined extract is dried over sodium sulfate.
Removal of solvent gives 4-cyclopropylmethylpiperidine-1,4-dicarboxylic acid monotertbutyl
ester.
Step (c)
This intermediate is prepared following the same procedure as that of
4-isobutylpiperidinecarboxylic acid [step (d) of intermediate XXX].
XXXII) 4-Isopropyl-piperidinecarboxylic acid
This intermediate is prepared following the same procedure as that of 4-
cyclopropylmethyl-piperidinecarboxylic acid (XXXI).
XXXIII) 4-Thiophenylmethylpiperidinecarboxylic acid ethyl ester
Step (a)
Methanesulphonyl chloride (6.2 mL, 0.0797 mol) is added dropwise to a solution of
thiophenemethanol (7.0 g, 0.0613 mol) and triethyl amine (12.8 mL, 0.0920 mol) in
dichloromethane (70 mL) at 0-5C. The reaction mixture is allowed to stir at room
temperature for 30 min. Demineralized water (25 mL) is added to the reaction mixture and
the organic layer is separated. The aqueous layer is extracted with dichloromethane (1 x 25
mL). Combined organic layer is dried over anhydrous sodium sulfate. Removal of solvent
under reduced pressure gives methanesulfonic acid thiophenylmethyl ester.
n-Butyllithium (15% solution in n-hexane; 10 mL, 0.023 mol) is added to a stirred
solution of diisopropyl amine (3.5 mL, 0.025 mol) in tetrahydrofuran (25 mL) at -70 C under
an atmosphere of nitrogen and stirred for 30 minutes. A solution of piperdine-1,4-dicarboxylic
acidtert-butyl esterethyl ester (3 gm, 0.012 mol) in tetrahydrofuran (10 mL) is introduced
at -70 C. Hexamethyl phospharamide (4.8 mL) is added and reaction mixture is allowed to
stir till the temperature reaches at -45 C. Reaction mixture is again cooled to -70 C,
methanesulfonic acid thiophenylmethyl ester (5.8 gm, 0.030 mol) in tetrahydrofuran (10
mL) is added and stirred for 45 minutes. Demineralized water (15 mL) is added slowly into
the reaction mixture at 0 C and stirred for 10 minutes. It is extracted with ethyl acetate (2x15
mL). Combined organic layer is dried over sodium sulfate. Removal of solvent under reduced
pressure gives a crude residue which is purified by column chromatography (230-400 mesh,
ethyl acetate:n-hexane 15:85) to furnish 4-thiophenylmethylpiperidine-1,4-dicarboxylic
acidtert-butyl esterethyl ester.
Step (b)
This intermediate is prepared by following the same procedure as that of 4-
methylpiperidinecarboxylic acid ethyl ester [step (b) of intermediate V].
XXXIV) 4-Furanylmethyl-piperidinecarboxylic acid ethyl ester
This intermediate is prepared following the same procedure as that of 4-thiophen
ylmethylpiperidinecarboxylic acid ethyl ester (XXXIII).
XXXV) 4-(3-Piperidinyl-propyl)-piperidinecarboxylic acid ethyl ester
Step (a)
This compound is prepared following the same procedure as that of 4-
benzyloxymethylpiperidine-1,4-dicarboxylic acidtert-butyl ester ethyl ester [step (a) of
intermediate (XVIII)].
Step (b)
This compound is prepared following the same procedure as that of 4-
hydroxymethylpiperidine-1,4-dicarboxylic acid 1-tert-butyl esterethyl ester [step (b) of
intermediate (XVIII)].
Step (c)
Carbon tetrabromide (1.6 gm, 0.0048 mol) is added to a stirred solution of 4-(3-
hydroxypropyl) piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester (1.27 gm,
0.0040 mol) and triphenyl phosphine (1.6 gm, 0.0060 mol) in dichloromethane (15 mL) at 0-
C temperature. Reaction mixture is allowed to stir at room temperature for 30 minutes.
Removal of solvent gives a crude residue which is purified by column chromatography (silica
gel 230-400 mesh, ethyl acetate:n-hexane 3:7) to get 4-(3-bromopropyl)piperidine-1,4-
dicarboxylic acidtert-butyl esterethyl ester.
Step (d)
Piperidine (0.13 mL, 0.00132 mol) is added to a solution of 4-(3-
bromopropyl)piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester (0.1 gm, 0.00026
mol) in tetrahydrofuran (5 mL). The reaction mixture is heated at 60-65 C for 3 hours. It is
then cooled to room temperature, treated with demineralized water (12 mL) and extracted
with ethyl acetate (2x20 mL). Combined extract is dried over sodium sulphate and
concentrated under reduced pressure to get a crude residue which is purified by column
chromatography (silica gel 230-400 mesh, methanol:dichloromethane, 1:9) to yield 4-(3-
piperidinyl propyl)piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester.
Step (e)
This intermediate is prepared following the same procedure as that of 4-
hydroxymethylpiperidinecarboxylic acid ethyl ester [step (c) of intermediate (XVIII)].
XXXVI) 4-(3-Pyrrolidinyl-propyl)-piperidinecarboxylic acid ethyl ester
This intermediate is prepared following the same procedure as that of 4-(3-piperidin-
1-yl-propyl)-piperidinecarboxylic acid ethyl ester (XXXV).
PREPARATION OF COMPOUNDS OF INVENTION
The process for preparation of some of the representative compounds of the present
invention are mentioned herein below. Such disclosures are simply for illustrative purposes
and should not be considered as limiting the invention.
Example 1: 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methylpiperidinecarboxylic acid
Step (a)
Cl Cl
OH O N
N,N’-Dicyclohexylcarbodiimide (0.615 g, 0.003 mol) is added to a solution of 3-chloro-
4-cyclohexyl benzoic acid (0.475 g, 0.002 mol), N-hydroxyhydroxymethylbenzamidine
(0.45 g, 0.003 mol) and N-hydroxybenzotriazole monohydrate (0.457 g, 0.003 mol) in N,N-
dimethylformamide (10 mL). The reaction mixture is stirred at 130-135°C for 2 hrs. It is then
cooled to 0-5°C, filtered and washed with dichloromethane (2x20 mL). The filtrate is
evaporated under reduced pressure and the residue is treated with demineralized water
(20 mL). It is extracted with ethyl acetate (3x15 mL) and the combined extract is dried over
sodium sulfate. Removal of solvent under reduced pressure gives a crude residue which is
purified by column chromatography (silica gel 230-400, ethyl acetate:toluene, 15:85) to give
{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]phenyl}methanol.
Step (b)
Cl Cl
OH Cl
O N O N
Thionyl chloride (0.27 mL, 0.0037 mol) and N,N-dimethylformamide (0.1 mL) are
added to a stirred solution of {4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazol
yl]phenyl}methanol (0.45 g, 0.0012 mol) in dichloromethane (10 mL) at 0°C. The reaction
mixture is heated at 40-45°C and is stirred at this temperature for 1 hr. It is then cooled to 0-
C temperature, treated with demineralized water (3 mL) and is neutralized with 4N sodium
hydroxide solution at 0-5°C to adjust the pH 8-9. Finally it is extracted with dichloromethane
(2x10 mL) and the combined extract is dried over sodium sulfate. Removal of solvent under
reduced pressure gives 5-(3-chlorocyclohexylphenyl)(4-chloromethylphenyl)-[1,2,4]-
oxadiazole.
Step (c)
Potassium carbonate (0.16 g, 0.0012 mol) and 4-methylpiperidinecarboxylic acid
ethyl ester (0.21 g, 0.0012 mol) are added to a solution of 5-(3-chlorocyclohexylphenyl)
(4-chloromethylphenyl)-[1,2,4]-oxadiazole (0.3 g, 0.00077 mol) in N,N-dimethylformamide (
mL). The reaction mixture is heated at 65-70°C for 2 hrs. Removal of solvent gives a
crude residue which is purified by column chromatography (silica gel 230-400 mesh, ethyl
acetate:toluene, 1:4 ) to give 4-methyl{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-
oxadiazolyl]benzyl}piperidinecarboxylic acid ethyl ester.
Step (d)
Cl Cl
N O N OH
O N O N
A solution of sodium hydroxide (0.1 g, 0.0023 mol) and potassium hydroxide (85%
assay, 0.13 g, 0.0020 mol) in demineralized water (2 mL) is added to a solution of 4-methyl-
1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} piperidinecarboxylic
acid ethyl ester (0.3 g, 0.00057 mol) in tetrahydrofuran and ethanol (14 mL, 1:1). The
reaction mixture is heated under reflux (80°C) for 2 hrs. It is then concentrated under
reduced pressure to give a crude residue which is dissolved in demineralized water (10 mL)
and acidified to pH~4-5 with 20% aqueous acetic acid solution. The resultant solid is filtered,
dried and washed with acetone (2x10 mL). Solid is dried under vacuum to get 1-{4-[5-(3-
chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl}4-methyl piperidinecarboxylic acid.
Example 2: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methylpiperidinecarboxylic acid, tert-butylamine salt
Step (a)
Cl Cl
OH O N
N,N’-Dicyclohexylcarbodiimide (1.07 g, 0.0052 mol) is added to a solution of 3-chloro-
4-isobutylbenzoic acid (0.74 g, 0.0035 mol), N-hydroxyhydroxymethylbenzamidine
(0.867g, 0.0052 mol) and N-hydroxybenzotriazole monohydrate (0.798 g, 0.0052 mol) in N,N-
dimethylformamide (15 mL). The reaction mixture is heated at 120-125 C for 2 hrs. It is then
cooled to 0-5°C, filtered and washed with dichloromethane (2x20 mL). The filtrate is
evaporated under reduced pressure and the residue is treated with demineralized water
(20 mL). It is extracted with ethyl acetate (2x30 mL) and the combined extract is dried over
sodium sulfate. Removal of solvent under reduced pressure gives a crude residue which is
purified by column chromatography (silica gel 230-400, ethyl acetate:toluene, 15:85) to give
{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-phenyl}methanol.
Step (b)
Cl Cl
OH Cl
O N O N
Thionyl chloride (3.1 mL, 0.043 mol) and N,N-dimethylformamide (0.2 mL) are added
to a stirred solution of {4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-phenyl}
methanol (4.9 g, 0.0143 mol) in dichloromethane (30 mL) at 0°C. The reaction mixture is
heated at 40-45°C and is stirred at this temperature for 30 minutes. It is then cooled to 0-5 C
temperature, treated with demineralized water (3 mL) and neutralized with caustic lye to
adjust the pH to 8-9. Finally it is extracted with dichloromethane (2x20 mL) and the combined
extract is dried over sodium sulfate. Removal of solvent under reduced pressure gives 5-(3-
chloroisobutylphenyl)(4-chloromethylphenyl)-[1,2,4]-oxadiazole.
Step (c)
Cl Cl
Cl N
N N O
O N O N
Potassium carbonate (0.29 g, 0.0021 mol) and 4-methylpiperidinecarboxylic acid
ethyl ester (0.36 g, 0.0021 mol) are added to a solution of 5-(3-chloroisobutylphenyl)(4-
chloromethylphenyl)-[1,2,4]-oxadiazole (0.5 g, 0.0014 mol) in N,N-dimethylformamide
(10 mL). The reaction mixture is heated at 65-70°C for 2 hours. Removal of solvent gives a
crude residue which is purified by column chromatography (silica gel 230-400 mesh,
toluene:ethyl acetate 4:1) to give 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-
benzyl}methylpiperidinecarboxylic acid ethyl ester.
Step (d)
O N NH
A solution of sodium hydroxide (0.22 g, 0.0055 mol) and potassium hydroxide (85%
assay, 0.3 g, 0.0046 mol) in demineralized water (1 mL) is added to a solution of 1-{4-[5-(3-
chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidinecarboxylic acid
ethyl ester (0.67 g, 0.0014 mol) in (14 mL) of tetrahydrofuran and ethanol mixture (1:1). The
reaction mixture is heated at 80ºC temperature for 4 hrs. It is then concentrated under
reduced pressure to give a crude residue which is treated with demineralized water (20 mL)
and acidified to pH~4-5 with 20% aqueous acetic acid solution (10 mL). The resultant solid is
filtered, dried and washed with demineralized water (1x20 mL) and acetone (2x5 mL)
respectively. The resultant solid is treated with a solution of methanol, dichloromethane and t-
butylamine (2:7.5:0.5, 20 mL) and concentrated under reduced pressure. The solid mass is
purified by column chromatography (silica gel 230-400 mesh, methanol:dichloromethane:t-
butylamine,1:8.9:0.1) to get 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}-
4-methylpiperidinecarboxylic acid t-butyl amine salt.
Example 3: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methylpiperidinecarboxylic acid
Cl Cl
O OH
O N O N
An aqueous solution of 20% acetic acid (1 mL) is added to a slurry of 1-{4-[5-(3-
chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidinecarboxylic acid t-
butyl amine salt (0.2 g, 0.00035 mol) in demineralized water (10 mL) to adjust the pH of the
solution to 4 - 5. The solution is stirred at room temperature for 30 minutes, filtered and
washed with demineralized water (2x5 mL) & acetone (1x5 mL). Finally it is dried to get 1-{4-
[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidinecarboxylic
acid as free acid.
Example 4: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methylpiperidinecarboxylic acid, sodium salt
Cl Cl
N OH N O
O N O N Na
An aqueous solution of sodium hydroxide (0.006 g, 0.00015 mol) is added to a slurry
of 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidine
carboxylic acid (0.065 g, 0.00014 mol) in tetrahydrofuran (5 mL). The solution is stirred at
room temperature for 30 minutes and concentrated under reduced pressure to get sodium
salt of 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidine
carboxylic acid.
Examples 5 & 6 may be prepared in the manner as mentioned for sodium salt
(Example 4).
Example 5: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methylpiperidinecarboxylic acid, arginine salt
N OH
OH NH
N NH
Example 6: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methylpiperidinecarboxylic acid, potassium salt
Example 7: 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methylpiperidinecarboxylic acid
N OH
A solution of sodium hydroxide (0.13 g, 0.0033 mol) and potassium hydroxide (85%
assay, 0.22 g, 0.0033 mol) in demineralized water (5 mL) is added to a solution of 1-{4-[5-(3-
chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidinecarboxylic
acid ethyl ester (0.43 g, 0.0008 mol) in a mixture of tetrahydrofuran and ethanol (1:1), 10 ML.
The reaction mixture is heated at 80ºC temperature for 3 hrs. It is then concentrated under
reduced pressure to give a crude residue which is treated with demineralized water (20 mL)
and acidified to pH~4-5 with 20% aqueous acetic acid solution (10 mL). The resultant solid is
filtered, dried and washed with demineralized water (1x20 mL) and acetone (2x5 mL)
respectively. Finally it is dried under reduced pressure to get 1-{4-[5-(3-chloro
cyclopentylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidinecarboxylic acid.
Example 8: 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}
methylpiperidinecarboxylic acid
N OH
Example 8 may be prepared in a manner as mentioned above for Example 7.
Example 9: 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methoxymethylpiperidinecarboxylic acid tert-butyl amine salt
Step (a)
Potassium carbonate (0.28 g, 0.002 mol) and 4-methoxymethylpiperidinecarboxylic
acid ethyl ester (0.4 g, 0.002 mol) are added to a solution of 5-(3-Chlorocyclopentyl-
phenyl)(4-chloromethyl-phenyl)-[1,2,4]oxadiazole (0.5 g, 0.0013 mol) in N,N-
dimethylformamide (15 mL). The reaction mixture is heated at 65-70°C for 2 hours. Removal
of solvent gives a crude residue which is purified by column chromatography (silica gel 230-
400 mesh, toluene:ethyl acetate 4:1) to give 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-
oxadiazolyl]benzyl}methoxy methyl piperidinecarboxylic acid ethyl ester.
Step (b)
N O N OH
O N O N
Potassium hydroxide powder (85% assay, 0.32 g, 0.0049 mol) and 18-crownether
(0.01 g) are added to a solution of 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazol
yl]benzyl}methoxymethylpiperidinecarboxylic acid ethyl ester (0.3 g, 0.00056 mol) in dry
toluene (15 mL). The reaction mixture is refluxed for 3 hrs. It is then concentrated under
reduced pressure and the residue is acidified to pH~ 4-5 with 20% aqueous solution of acetic
acid (10 mL). The precipitated solid is filtered, dried and washed with demineralised water
(2x10 mL) and acetone (2x5 mL). Solid mass is dissolved in a solution of
methanol:dichlromethane:t-butylamine (1:8.9:0.1; 5 mL) and concentrated under reduced
pressure to get crude residue which is purified by column chromatography (silica gel 230-400
mesh, methanol:dichloromethane:t-butylamine,1:8.9:0.1) to give 1-{4-[5-(3-chloro
cyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methoxymethylpiperidinecarboxylic
acid.
Examples 10 to 28 may be prepared in similar manner as that mentioned for Example
Example 10: 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
methoxymethylpiperidinecarboxylic acid tert-butyl amine salt
Example 11: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
ethylpiperidinecarboxylic acid tert-butyl amine salt
N OH
Example 12: 4-allyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazol
yl]benzyl}piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 13: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
propylpiperidinecarboxylic acid tert-butyl amine salt
N OH
Example 14: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2-
methoxyethoxymethyl)piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 15: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}
hydroxymethylpiperidinecarboxylic acid tert-butyl amine salt
N OH
Example 16: 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]oxadiazolyl]-benzyl}
methoxymethylpiperidinecarboxylic acid tert-butyl amine salt
ON O
Example 17: 4-Allyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-
benzyl}piperidinecarboxylic acid tert-butyl amine salt
N OH
ON 2
Example 18: 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}
propylpiperidinecarboxylic acid tert-butyl amine salt
N OH
Example 19: 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-
methoxyethoxymethyl)piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 20: 4-Benzyloxymethyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-
benzyl}piperidinecarboxylic acid tert-butyl amine salt
N OH
ON O
Example 21: 4-Benzyloxymethyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazol
yl]-benzyl}piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 22: 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}
hydroxymethylpiperidinecarboxylic acid tert-butyl amine salt
ON OH
Example 23: 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]- oxadiazolyl]-benzyl}
phenylpiperidinecarboxylic acid tert-butyl amine salt
N OH
NH Ph
Example 24: 4-Benzyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}-
piperidinecarboxylic acid tert-butyl amine salt
ON Ph
Example 25: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(4-fluoro-benzyl)-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 26: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(2-fluoro-benzyl)-piperidinecarboxylic acid tert-butyl amine salt
Example 27: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(4-methoxy-benzyl)-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 28: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}
(2-methoxy-benzyl)-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 29: 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}
methoxymethylpiperidinecarboxylic acid tert-butyl amine salt
O OH
O Cl 2
Potassium hydroxide powder (85% assay, 0.394 g, 0.0060 mol) and N-methyl-N,N-
dioctyloctanammonium chloride (0.02 g) are added to a solution of 1-{4-[5-(2-
chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methoxymethylpiperidinecarboxylic
acid ethyl ester (0.38 g, 0.00069 mol) in N,N'-dimethyl formamide (5 mL). The reaction
mixture is stirred at 80ºC temperature for 2 hrs. It is then cooled to room temperature and
acidified with 20% aqueous acetic acid solution to pH~5-6. The precipitated solid is filtered,
dried and washed with (2x5 mL) acetone. The solid mass is purified by column
chromatography (silica gel 230-400 mesh, methanol:dichloromethane:t-butylamine,1:8.9:0.1)
to give 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methoxymethyl-
piperidinecarboxylic acid.
Example 30: 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}
ethylpiperidinecarboxylic acid tert-butyl amine salt
Step (a)
N,N’-Dicyclohexylcarbodiimide (4 g, 0.019 mol) is added to a solution of 2-
chlorobiphenylcarboxylic acid (3 g, 0.013 mol), N-hydroxyhydroxymethyl benzamidine
(2.9 g, 0.017 mol) and N-hydroxybenzotriazole monohydrate (2.9 g, 0.019 mol) in N,N-
dimethylformamide (40 mL). The reaction mixture is heated at 120-125 C for 3 hrs. It is then
cooled to 0-5°C, filtered and washed with dichloromethane (2x15 mL). The filtrate is
evaporated under reduced pressure and the residue is treated with demineralized water (20
mL). It is extracted with ethyl acetate (2x20 mL) and the combined extract is dried over
sodium sulfate. Removal of solvent under reduced pressure gives a crude residue which is
purified by column chromatography (silica gel 230-400, ethyl acetate:toluene, 1:9) to give {4-
[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-phenyl}-methanol.
Step (b)
Pyridiniumchlorochromate (3.6 g, 0.017 mol) is added to a solution of {4-[5-(2-
chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-phenyl}-methanol (4.0 g, 0.011 mol) in
dichloromethane (40 mL). The reaction mixture is stirred at room temperature for 30 minutes,
filtered and washed with dichloromethane (40 mL). Filtrate is concentrated under reduced
pressure to give crude which is purified by column chromatography (230;400 mesh: 9.5:0.5
toluene : ethyl acetate) to yield 4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-
benzaldehyde.
Step (c)
A solution of 4-ethylpiperidinecarboxylic acid (0.45 g, 0.00283 mol) in
demineralized water (3 mL) is added to a solution of 4-[5-(2-chloroisobutylphenyl)-[1,2,4]-
oxadiazoleyl]benzaldehyde (0.685 gm, 0.0019 mol) in methanol and dichloromethane (1:3,
mL). Acetic acid (1.1 mL) is added to the reaction mixture. The reaction mixture is stirred
at room temperature for 30 minutes. A solution of sodium cyanoborohydried (0.238 gm,
0.0038 mol) in methanol (2 mL) is added to the reaction mixture and stirred for 1.5 hrs at
room temperature. Solvent is removed from the reaction mixture under reduced pressure to
get a crude solid which is treated with demineralized water (10 mL) and filtered. Solid mass
is dissolved in a solution of methanol:dichlromethane:t-butylamine (1:8.9:0.1; 15 mL) and
concentrated under reduced pressure to get crude residue which is purified by column
chromatography (silica gel 230-400 mesh, methanol:dichloromethane:t-butylamine,1:8.9:0.1)
to give 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}ethylpiperidine
carboxylic acid.
Example 31 may be prepared in a manner as mentioned above for Example 2.
Example 31: 1-{4-[5-(4-Isobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-
piperidinecarboxylic acid tert-butyl amine salt
Example 32: 1-{4-[5-(3-Chloroisobutylphenyl-[1,2,4]-oxadiazolyl]benzyl}(4-
methoxybutyl)piperidinecarboxylic acid tert-butyl amine salt
N OH
ON O
An aqueous solution (0.5 mL) of potassium hydroxide (0.39 g, 0.0059 mol, assay
85%) is added to a solution of 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazol
yl]benzyl}(4-methoxybutyl)piperidinecarboxylic acid ethyl ester (0.48 g, 0.0008 mol) in a
mixture of tetrahydrofuran (5 mL) and ethanol (5 mL). The reaction mixture is heated at 75-
80ºC for 20 hrs, cooled to room temperature and then concentrated under reduced pressure.
The residue is treated with demineralized water (10 mL) and acidified to pH~5-5.5 using 20%
aqueous acetic acid (15 mL). The precipitated solid is filtered, washed with demineralized
water (10 mL) and acetone (10 mL). The Solid mass is dissolved in a solution of
methanol:dichlromethane:t-butylamine (1:8.9:0.1; 5 mL) and concentrated under reduced
pressure to get crude residue which is purified by column chromatography (silica gel 230-400
mesh, methanol:dichloromethane:t-butylamine,1:8.9:0.1) to give 1-{4-[5-(3-chloro
isobutylphenyl-[1,2,4]-oxadiazolyl]benzyl}(4-methoxybutyl)piperidinecarboxylic acid.
Example 33: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2-
methoxyethoxymethyl)piperidinecarboxylic acid potassium salt
N OH
ON O
1-{4-[5-(3-chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-methoxy-
ethoxymethyl)-piperidinecarboxylic acid ethyl ester (6g, 0.01052 mol) is added in to a
solvent mixture containing THF (120ml, 20vol) and Rectified Spirit (120ml, 20vol). Stirred to
get a clear solution at RT. Potassium Hydroxide (4.17g, 0.06315mol) is charged in to the
above reaction flask at RT. The reaction mixture is heated at 70-80ºC temperature for 10-
12hrs. It is then concentrated under reduced pressure to give a crude residue which is
codistilled with acetone (12 ml, 2vol) and suspended in aq. Acetone [5% water, 90ml, 15vol].
Stirred the product slurry at 30-40 C for 30mins. Cooled to 0-5 C and stirred for 1-2hrs. The
resultant solid is filtered, dried and washed with aq. Acetone [5% water, 48ml, 8vol]. Suck
dried the product under nitrogen for 30-60mins and further dried under vacuum at 450C to
yield 7g [M/C: 12%] of Potassium salt of 1-{4-[5-(3-chloroisobutyl-phenyl)-[1,2,4]oxadiazol-
3-yl]-benzyl}(2-methoxy-ethoxymethyl)-piperidinecarboxylic acid.
The above product is leached with Ethyl acetate and dried under vacuum to yield 6.8g
of Potassium salt of 1-{4-[5-(3-chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-
methoxyethoxymethyl)-piperidinecarboxylic acid.
The potassium salt [6.15gm] is crystallized from Methanol to yield 4.5g of pure
Potassium salt of 1-{4-[5-(3-chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-
methoxy-ethoxymethyl)-piperidinecarboxylic acid.
Examples 34-35 may be prepared in a similar manner as that mentioned for Example
Example 34: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-
phenoxy-ethyl)-piperidinecarboxylic acid tert-butyl amine salt
Example 35:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2,6-
difluoro-benzyl)-piperidinecarboxylic acid tert-butyl amine salt
Examples 36-38 may be prepared in similar manner as that mentioned for Example
Example 36:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
isobutyl-piperidinecarboxylic acid tert-butyl amine salt
Example 37:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
isopropyl-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 38:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(3-
trifluoro methyl-benzyl)-piperidinecarboxylic acid tert-butyl amine salt
N OH
Examples 39 - 41 may be prepared in similar manner as that mentioned for Example
Example 39:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}furan-
2-ylmethyl-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 40:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
pyridinylmethyl-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 41:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}[2-(2-
methoxy-phenoxy)-ethyl]-piperidinecarboxylic acid tert-butyl amine salt
Examples 42-43 may be prepared in similar manner as that mentioned for Example 9.
Example 42:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
pyridinylmethyl-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 43:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
pyridinylmethyl-piperidinecarboxylic acid tert-butyl amine salt
Examples 44-47 may be prepared in similar manner as that mentioned for Example 2.
Example 44:1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
methyl-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 45:1-{4-[5-(4-tert-Butylchloro-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
methyl-piperidinecarboxylic acid tert-butyl amine salt
Example 46:1-{4-[5-(3-Chloropropyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-
piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 47:1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-
methoxy-ethoxymethyl)-piperidinecarboxylic acid tert-butyl amine salt
ON O
Examples 48-58 may be prepared in similar manner as that mentioned for Example 9
Example 48:1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
ethyl-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 49:4-Allyl{4-[5-(3-chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-
benzyl}-piperidinecarboxylic acid tert-butyl amine salt
Example 50:1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin
ylmethyl-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 51:1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-
methoxy-benzyl)-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 52:1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-fluoro-
benzyl)-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 53:1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-
methoxy-benzyl)-piperidinecarboxylic acid tert-butyl amine salt
Example 54:1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}
ethyl-piperidinecarboxylic acid tert-butyl amine salt
Example 55:4-Benzyl{4-[5-(2-chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}-
piperidinecarboxylic acid tert-butyl amine salt
Example 56:1-{4-[5-(3-Chlorocyclohexyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
pyridinylmethyl-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 57:1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
methoxymethyl-piperidinecarboxylic acid tert-butyl amine salt
N OH
ON O
Example 58:1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin
ylmethyl-piperidinecarboxylic acid tert-butyl amine salt
Example 59 may be prepared in similar manner as that mentioned for Example 2.
Example 59:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-
ethoxy-ethoxymethyl)-piperidinecarboxylic acid tert-butyl amine salt
N OH
Examples 60 may be prepared in similar manner as that mentioned for Example 9.
Example 60:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
isopropoxy methyl-piperidinecarboxylic acid tert-butyl amine salt
Examples 61 may be prepared in similar manner as that mentioned for Example 32.
Example 61:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
cyclopentyloxymethyl-piperidinecarboxylic acid tert-butyl amine salt
ON O
Examples 62 may be prepared in similar manner as that mentioned for Example 9.
Example 62:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
thiophenylmethyl-piperidinecarboxylic acid tert-butyl amine salt
Examples 63 may be prepared in similar manner as that mentioned for Example 30.
Example 63:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}
cyclopropylmethyl-piperidinecarboxylic acid tert-butyl amine salt
N OH
Examples 64-66 may be prepared in similar manner as that mentioned for Example 9.
Example 64:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-
morpholinyl-ethyl)-piperidinecarboxylic acid
N OH
Example 65: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3-
piperidinyl-propyl)-piperidinecarboxylic acid tert-butyl amine salt
N OH
Example 66: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3-
pyrrolidinyl-propyl)-piperidinecarboxylic acid tert-butyl amine salt
N OH
Ex. MS
Structure NMR data
No. (ES+)
as free form
PMR : (CDCl +CD OD+TFA; 400.13 MHz ;
ppm)
1.25-1.60 (s merged in m, 9H); 1.75-2.02 (br
494.24 m, 6H); 2.40 (d, J=14.64 Hz, 2H); 2.83-3.07
(br t, 2H); 3.07-3.19 (br t, 1H); 3.54-3.68 (br
d, 2H); 4.33 (s, 2H);7.42-7.62 (m, 3H); 8.05
(d, J=7.78 Hz, 1H); 8.17-8.27 (br d, 3H)
One exchangeable proton
as free form
PMR : (CDCl +CD OD+TFA; 400.13 MHz ;
ppm)
0.97 (d, J=5.99 Hz, 6H); 1.30 (s, 3H); 1.74-
O 1.88 (br t, 2H); 2.00-2.12 (br m, 1H); 2.35 (d,
468.23 J=14.49 Hz, 2H); 2.69-2.77 (br d, 2H); 2.89-
N OH
3.01 (br t, 2H); 3.48-3.59 (br d, 2H); 4.28 (s,
2H); 7.48-7.43 (br d, 1H); 7.54-7.62 (br d,
2H); 7.99-8.05 (br d, 1H); 8.18-8.27 (br d,
One exchangeable proton
As free form
PMR : (CDCl3 +CD3OD+TFA; 500.13 MHz ;
ppm)
1.29 (s, 3H); 1.57-1.67 (br m, 2H); 1.72-1.92
7 (br m, 6H); 2.12-2.22 (br m, 2H); 2.31 (d,
480.23
N OH
J=14.60 Hz, 2H); 2.88 (t, J=12.50 Hz, 2H);
O N 3.48-3.58 (br m, 3H); 4.36 (s, 2H); 7.50 (d,
J=7.15 Hz, 1H); 7.55 (d, J=7.95 Hz, 2H);
8.04 (d, J=8.00 Hz, 1H); 8.18-8.26 (br m, 3H)
One exchangeable proton
As free form
PMR:CDCl +CD OD+TFA; 500.13 MHz ;
d ppm)
1.29 (s, 3H); 1.81-1.90 (br t, 2H); 2.31 (d,
J=14.40 Hz, 2H); 2.86-2.95 (br t, 2H); 3.46-
8 488.24
N OH
3.53 (br d, 2H); 4.26 (s, 2H); 7.43-7.53 (br m,
5H); 7.55-7.64 (m, 3H); 8.16 (dd, J1=7.90 Hz,
J =1.00 Hz, 1H); 8.25 (d, J=8.05 Hz, 2H);
8.35 (s, J=0.90 Hz, 1H);
One exchangeable proton
as t-butyl amine salt
PMR : (CDCl3+D2O; 500.13 MHz ; d ppm)
1.28 (s, 9H); 1.55-1.65 (br m, 4H); 1.71-1.80
(br m, 2H); 1.80-1.89 (br m, 2H); 2.10-2.18
(br m, 4H); 2.38-2.46 (br t, 2H); 2.71-2.77 (br
9 510.21
d, 2H); 3.29 (s, 3H); 3.41 (s, 2H); 3.46-3.56
(m, 1H); 3.63 (s, 2H); 7.44-7.51 (m, 3H); 8.01
O N O
(d, J=8.30 Hz, 1H); 8.08 (d, J=8.05 Hz, 2H);
8.18 (d, J=0.90 Hz, 1H)
Three exchangeable protons
Ex. MS
Structure NMR data
No. (ES+)
as t-butyl amine salt
PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
1.29-1.31 (s merged in m, 10H); 1.37-1.54
(m, 4H); 1.54-1.63 (m, 2H); 1.78-1.85 (br d,
1H); 1.91 (t, J=13.20 Hz, 4H); 2.13 (d,
J=13.45 Hz, 2H); 2.37 (t, J=10.20 Hz, 2H);
524.21
N OH
2.74-2.82 (br d, 2H); 3.06-3.14 (m, 1H); 3.30
(s, 3H); 3.40 (s, 2H); 3.64 (s, 2H); 7.46-7.52
O N O
(m, 3H); 8.05 (dd, J1=8.20 Hz, J2=1.50 Hz,
1H); 8.10 (d, J=8.15 Hz, 2H); 8.19 (d, J=1.35
Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3+CD3OD; 500.13 MHz ; d ppm)
0.85 (t, J=7.45 Hz, 3H); 0.97 (d, J=6.60 Hz,
NH 6H); 1.26 (s, 9H); 1.42-1.57 (m, 4H); 2.01-
2.08 (m, 1H); 2.12 (d, J=13.40 Hz, 2H); 2.27
481.94
(t, J=11.00 Hz, 2H); 2.71 (d, J=7.20 Hz, 2H);
N OH
2.75—2.82 (br d, 2H); 3.60 (s, 2H); 7.38 (d,
J=8.00 Hz, 1H); 7.48 (d, J=8.05 Hz, 2H);
8.02 (dd, J =7.90 Hz, J =1.40 Hz, 1H); 8.10
(d, J=8.05 Hz, 2H); 8.20 (d, J=1.10 Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3+CD3OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.55 Hz, 6H); 1.26 (s, 9H); 1.48-
1.56 (br t, 2H); 2.00-2.13 (m, 3H); 2.24-2.34
(m, 4H); 2.70 (d, J=7.20 Hz, 2H); 2.72-2.79
493.94
(br d, 2H); 3.60 (s, 2H); 4.98-5.06 (m, 2H);
N OH
.73-5.83 (m, 1H); 7.38 (d, J=7.95 Hz, 1H);
7.48 (d, J=8.10 Hz, 2H); 8.01 (dd, J =7.90
Hz, J =1.15 Hz, 1H); 8.10 (d, J=8.10 Hz, 2H);
8.20 (d, J=1.25 Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
0.79 (t, J=7.10 Hz, 3H); 0.89 (d, J=6.55 Hz,
NH 6H); 1.15 (s, 9H); 1.16-1.24 (br m, 2H); 1.33-
1.45 (br m, 4H); 1.92-2.00 (m, 1H); 2.00-2.07
495.95 (br d, 2H); 2.12 (br t, 2H); 2.63 (d, J=7.20 Hz,
2H); 2.64-2.71 (br d, 2H); 3.50 (s, 2H); 7.30
(d, J=7.95 Hz, 1H); 7.39 (d, J=7.95 Hz, 2H);
7.94 (d, J=7.95 Hz, 1H); 8.02 (d, J=8.00 Hz,
2H); 8.12 (s, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl ; 400.13 MHz ; d ppm)
0.96 (d, J=6.61 Hz, 6H); 1.26 (s, 9H); 1.53-
N OH 542.04 1.63 (br t, 2H); 1.98-2.08 (m, 1H); 2.13-2.22
(br d, 2H); 2.35-2.44 (br t, 2H); 2.69 (d,
O N O
J=7.19 Hz, 2H); 2.73-2.80 (br d, 2H); 3.36 (s,
3H); 3.49 (s, 2H); 3.42-3.60 (br d, 4H); 3.62
Ex. MS
Structure NMR data
No. (ES+)
(s, 2H); 7.35 (7.97 Hz, 1H); 7.48 (d, J=8.04
Hz, 2H); 8.00 (dd, J =7.99 Hz, J =1.17 Hz,
1H); 8.09 (d, J=8.08 Hz, 2H); 8.20 (d, J=1.03
Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3+CD3OD+TFA; 500.13 MHz ;
ppm)
0.97 (d, J=6.60 Hz, 6H); 1.39 (s, 9H); 1.84-
1.95 (br t, 2H); 2.00-2.11 (m, 1H); 2.31 (d,
J=14.60 Hz, 2H); 2.71 (d, J=7.20 Hz, 2H);
N OH 483.96
3.02 (d, J=12.60 Hz, 2H); 3.54 (d, J=11.80
Hz, 2H); 3.66 (s, 2H); 4.27 (s, 2H); 7.39 (d,
J=7.95 Hz, 1H); 7.58 (d, J=8.10 Hz, 2H);
=7.95 Hz, J =1.55 Hz, 1H); 8.19-
8.01 (dd, J1 2
8.25 (m, 3H)
Four exchangeable protons
as t-butyl amine salt
PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.62 Hz, 6H); 1.29 (s, 9H); 1.53-
1.63 (br m, 2H); 1.98-2.09 (m, 1H); 2.09-2.17
(br d, 2H); 2.37 (t, J=10..67 Hz, 2H); 2.70 (d,
N OH
16 498.19 J=7.21 Hz, 2H); 2.74-2.82 (br d, 2H); 3.30 (s,
3H); 3.39 (s, 2H); 3.63 (s, 2H); 7.38 (d,
ON O
J=7.99 Hz, 1H); 7.49 (d, J=8.10 Hz, 2H);
8.01 (dd, J1=7.91 Hz, J2=1.36 Hz, 1H); 8.10
(d, J=8.10 Hz, 2H); 8.20 (d, J=1.28 Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3+CD3OD; 500.13 MHz ;
d ppm)
1.28 (s, 9H); 1.50-1.58 (br t, 2H); 2.11 (d,
O J=13.40 Hz, 2H); 2.26 (d, J=7.25 Hz, 2H);
2.28-2.36 (br t, 2H); 2.76-2.83 (br d, 2H);
N OH
17 513.93
3.63 (s, 2H); 4.99-5.07 (m, 2H); 5.73-5.82
(m, 1H); 7.43-7.52 (m, 7H); 7.55 (d, J=8.05
Hz, 1H); 8.12 (d, J=8.15 Hz, 2H); 8.16 (dd,
J =8.00 Hz, J = 1.60 Hz, 1H); 8.34 (d, J=1.50
Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3+CD3OD; 500.13 MHz ; d ppm)
0.88 (t, J=7.15 Hz, 3H); 1.25 (s, 9H); 1.27-
1.34 (m, 2H); 1.43-1.55 (m, 4H); 2.13 (d,
J=13.40 Hz, 2H); 2.26 (t, J=10.90 Hz, 2H);
18 N OH 515.95
Cl 2.74-2.82 (br d, 2H); 3.60 (s, 2H); 7.43-7.52
(m, 7H); 7.55 (d, J=7.95 Hz, 1H); 8.12 (d,
J=8.00 Hz, 2H); 8.16 (dd, J =8.00 Hz,
J =1.45 Hz, 1H); 8.34 (d, J=1.25 Hz, 1H)
Three exchangeable protons
Ex. MS
Structure NMR data
No. (ES+)
as t-butyl amine salt
PMR : (CDCl ; 400.13 MHz ; d ppm)
1.31 (s, 9H); 1.52-1.62 (br t, 2H); 2.13-2.22
(br d, 2H); 2.34-2.45 (br t, 2H); 2.73-2.82 (br
N OH
19 561.99
d, 2H); 3.37 (s, 3H); 3.48 (s, 2H); 3.52-3.59
ON O
(br s, 4H); 3.62 (s, 2H); 7.41-7.56 (m, 8H);
8.09-8.17 (m, 3H); 8.34 (s, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : ( CDCl3; 500.13 MHz ; d ppm)
1.21 (s, 9H); 1.60-1.68 (br t, 2H); 2.17 (d,
J=13.45 Hz, 2H); 2.37-2.47 (br t, 2H); 2.71-
N 2.78 (br d, 2H); 3.49 (s, 2H); 3.62 (s, 2H);
594.00
N OH
4.48 (s, 2H); 7.28-7.32 (m, 5H); 7.43-7.50
(m, 7H); 7.52 (d, J=8.00 Hz, 1H); 8.09 (d,
J=8.20 Hz, 2H); 8.13 (dd, J =8.00 Hz,
J =1.70 Hz, 1H); 8.32 (d, J=1.50 Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR :(CDCl +CD OD+D O; 500.13 MHz ;
3 3 2
ppm)
0.96 (d, J=6.60 Hz, 6H); 1.21 (s, 9H); 1.57-
O 1.66 (br t, 2H); 1.98-2.07 (m, 1H); 2.15 (d,
J=13.15 Hz, 2H); 2.38-2.48 (br t, 2H); 2.66-
21 574.03
Cl 2.75 (d merged in m, 4H); 3.49 (s, 2H); 3.61
ON O
(s, 2H); 4.47 (s, 2H); 7.23-7.31 (m, 5H); 7.35
(d, J=8.10 Hz, 1H); 7.46 (d, J=8.10 Hz, 2H);
7.99 (dd, J1=7.95 Hz, J2=1.15 Hz, 1H); 8.07
(d, J=8.15 Hz, 2H); 8.19 (d, J=1.45 Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : CDCl3+CD3OD+TFA; 500.13 MHz ;
d ppm)
1.38 (s, 9H); 1.87-1.97 (br t, 2H); 2.30 (d,
J=14.55 Hz, 2H); 2.99 (t, J=12.50 Hz, 2H);
22 N OH 503.91 3.53 (d, J=12.05 Hz, 2H); 3.65 (s, 2H); 4.26
(s, 2H); 7.43-7.50 (m, 5H); 7.56 (d, J=8.00
ON OH
Hz, 1H); 7.60 (d, J=8.10 Hz, 2H); 8.16 (dd,
J =8.00 Hz, J =1.35 Hz, 1H); 8.25 (d, J=8.15
Hz, 2H); 8.35 (d, J=1.50 Hz, 1H)
Four exchangeable protons
as t-butyl amine salt
PMR : CDCl +CD OD+TFA; 500.13 MHz ;
d ppm)
0.98 (d, J=6.65 Hz, 6H); 1.37 (s, 9H); 2.01-
N 2.11 (m, 1H); 2.18-2.27 (br dt, 2H); 2.72 (d,
23 530.19
N J=7.20 Hz, 2H); 2.81 (d, J=13.90 Hz, 2H);
3.05 (t, J=12.90 Hz, 2H); 3.65-3.72 (br d,
2H); 4.32 (s, 2H); 7.33-7.39 (m, 5H); 7.40 (d,
J=8.05 Hz, 1H); 7.60 (d, J=8.20 Hz, 2H);
8.03 (dd, J1=7.90 Hz, J2=1.60 Hz, 1H); 8.20-
8.27 (m, 3H) Three exchangeable protons
Ex. MS
Structure NMR data
No. (ES+)
as t-butyl amine salt
PMR : CDCl +CD OD+TFA; 500.13 MHz ;
d ppm)
0.86 (d, J=6.50 Hz, 6H); 1.31 (s, 9H); 1.82-
1.98 (m, 3H); 2.21-2.27 (br d, 2H); 2.61 (d,
J=7.15 Hz, 2H); 2.71-2.84 (s merged in m,
24 544.22
N OH
4H); 3.50-3.57 (br d, 2H); 4.17 (s, 2H); 6.92-
6.98 (br d, 2H); 7.13-7.17 (br s, 3H); 7.29 (d,
J=7.95 Hz, 1H); 7.42 (d, J=7.85 Hz, 2H);
7.90 (d, J=7.80 Hz, 1H); 8.10 (d, J=3.55 Hz,
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3+CD3OD+TFA; 500.13 MHz ;
d ppm)
0.98 (d, J=6.65 Hz, 6H); 1.40 (s, 9H); 1.83-
N 1.93 (br dt, 2H); 2.02-2.10 (m, 1H); 2.30-2.35
N OH
(br d, 2H); 2.74 (d, J=7.25 Hz, 2H); 2.88 (s,
562.17
2 2H); 2.96 (t, J=13.05 Hz, 2H); 3.52-3.58 (br
d, 2H); 4.28 (s, 2H); 6.96 (t, J=8.65 Hz, 2H);
7.04-7.09 (m, 2H); 7.42 (d, J=7.95 Hz, 1H);
7.57 (d, J=8.20 Hz, 2H); 8.03 (dd, J =7.85
Hz, J2=1.75 Hz, 1H); 8.20-8.24 (m, 3H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3+CD3OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.60 Hz, 6H); 1.26 (s, 9H); 1.53-
1.61 (br t, 2H); 2.01-2.13 (m, 3H); 2.22-2.28
(br t, 2H); 2.71 (d, J=7.25 Hz, 2H); 2.77-2.84
N OH
26 562.19 (br d, 2H); 2.88 (s, 2H); 3.57 (s, 2H); 6.95-
7.04 (m, 2H); 7.13-7.22 (m, 2H); 7.38 (d,
J=7.95 Hz, 1H); 7.46 (d, J=8.15 Hz, 2H);
8.02 (dd, J1=7.90 Hz, J2=1.40 Hz, 1H); 8.08
(d, J=8.15 Hz, 2H); 8.20 (d, J=1.40 Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3+CD3OD+TFA; 500.13 MHz ;
d ppm)
0.98 (d, J=6.45 Hz, 6H); 1.37 (s, 9H); 1.82-
N 1.91 (m, 2H); 2.03-2.10 (m, 1H); 2.27-2.34
N OH
(br d, 2H); 2.73 (d, J=7.10 Hz, 2H); 2.84 (s,
2 574.23
2H); 2.88-2.97 (br t, 2H); 3.47-3.53 (br d,
2H); 3.78 (s, 3H); 4,25 (s, 2H); 6.81 (d,
J=8.35 Hz, 2H); 7.02 (d, J=8.25 Hz, 2H);
7.40-7.44 (br d, 1H); 7.57 (d, J=8.05 Hz, 2H);
8.03 (d, J=7.90 Hz, 1H); 8.20-8.25 (br d, 3H)
Three exchangeable protons
Ex. MS
Structure NMR data
No. (ES+)
as t-butyl amine salt
PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.55 Hz, 6H); 1.26 (s, 9H); 1,53-
O 1.61 (br t, 2H); 2.01-2.10 (m, 3H); 2.20-2.26
(br t, 2H); 2.70 (d, J=7.20 Hz, 2H); 2.78-2.82
N OH
28 574.23 (br d, 2H); 2.90 (s, 2H); 3.56 (s, 2H); 3.76 (s,
3H); 6.80-6.85 (m, 2H); 7.10-7.18 (m, 2H);
7.37 (d, J=8.00 Hz, 1H); 7.45 (d, J=8.05 Hz,
2H); 8.01 (d, J=7.95 Hz, 1H); 8.08 (d, J=8.00
Hz, 2H); 8.20 (s, 1H)
Three exchangeable protons
as t-butyl amine salt
O N PMR : (CDCl +CD OD; 400.13 MHz ; d ppm)
CO H
1.30 (s, 9H); 1.53-1.64 (br m, 2H); 2.10-2.18
CH OCH
(br d, 2H); 2.33-2.42 (br t, 2H); 2.74-2.82 (br
29 518.17
d, 2H); 3.31 (s, 3H); 3.37-3.43 (br s, 2H);
Cl NH
3.64 (s, 2H); 7.42-7.53 (m, 7H); 7.53 (d,
J=10.31 Hz, 1H); 8.11-8.18 (m, 3H); 8.34 (d,
J=1.17 Hz, 1H) Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl +CD OD+TFA; 400.13 MHz ;
d ppm)
CO H
0.88 (t, J=7.34 Hz, 3H); 1.40 (s, 9H); 1.60-
N 1.70 (m, 2H); 1.73-1.85 (br t, 2H); 2.37 (d,
N 502.19 J=14.65 Hz, 2H); 2.93 (t, J=12.51 Hz, 2H);
3.57 (d, J=12.32 Hz, 2H); 4.29 (s, 2H); 7.43-
7.54 (br m, 4H); 7.56-7.62 (m, 3H); 8.23-8.28
(br d, 2H); 8.34-8.37 (br s, 1H)
Two protons are merged between 8.1-8.2,
Three exchangeable protons
as t-butyl amine salt
NH PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
0.93 (d, J=6.50 Hz, 6H); 1.16 (s, 3H); 1.28
(s, 9H); 1.46-1.55 (br m, 2H); 1.89-1.99 (m,
434.18
1H); 2.09-2.15 (br d, 2H); 2.31-2.39 (br t,
N OH
2H); 2.58 (d, J=7.25 Hz, 2H); 2.70-2.78 (br d,
2H); 3.64 (s, 2H); 7.34 (d, J=7.15 Hz, 2H);
7.48 (d, J=8.15 Hz, 2H); 8.09-8.14 (m, 4H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.56 Hz, 6H); 1.26 (s, 9H); 1.29-
1.36 (br m, 2H); 1.41-1.58 (m, 6H); 2.00-2.09
(m, 1H); 2.11-2.18 (br d, 2H); 2.21-2.29 (br t,
32 NH
540.23
2H); 2.71 (d, J=7.19 Hz, 2H); 2.74-2.81 (br d,
2H); 3.31 (s, 3H); 3.36-3.40 (br m, 2H); 3.59
(s, 2H); 7.39 (d, J=8.02 Hz, 1H); 7.47 (d,
N OH
O J=8.04 Hz, 2H); 8.02 (d, J=6.90 Hz, 1H);
8.10 (d, J=8.04 Hz, 2H); 8.21 (s, 1H) Three
exchangeable protons
Ex. MS
Structure NMR data
No. (ES+)
As potassium salt :
PMR : (CDCl3 + CD3OD; 500.13 MHz ; d
ppm) 0.96 (d, J=6.60 Hz, 6H); 1.39-1.46 (br t,
2H); 2.00-2.09 (m, 1H); 2.10-2.16 (br d, 2H);
N OH
542.04 2.22-2.30 (br t, 2H); 2.65-2.72 (d merged in
m, 4H); 3.35 (s, 3H); 3.43 (s, 2H); 3.50-3.56
ON O
(m, 6H); 7.37 (d, J=7.95 Hz, 1H); 7.46 (d,
J=8.05 Hz, 2H); 8.01 (dd, J1=7.90 Hz,
J2=1.45 Hz, 1H); 8.09 (d, J=8.10 Hz, 2H);
8.20 (d, J=1.40 Hz, 1H)
as t-butyl amine salt
PMR : (CDCl3 +CD3OD+TFA; 400.13 MHz ; d
ppm) 0.96 (d, J=6.53 Hz, 6H); 1.41 (s, 9H);
1.86-1.98 (br t, 2H); 1.98-2.10 (m, 1H); 2.13-
2.20 (br t, 2H); 2.50-2.58 (br d, 2H); 2.71 (d,
N OH J=7.16 Hz, 2H); 3.06 (t, J=13.04 Hz, 2H);
574.21
3.60-3.67 (br d, 2H); 4.02-4.09 (br t, 2H);
4.33 (s, 2H); 6.78 (d, J=8.13 Hz, 2H); 6.95 (t,
J=7.27 Hz, 1H); 7.21-7.27 (br t, 2H); 7.41 (d,
J=8.01 Hz, 1H); 7.56 (d, J=7.84 Hz, 2H);
8.00 (d, J=7.87 Hz, 1H); 8.16-8.22 (m, 3H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.55 Hz, 6H); 1.28 (s, 9H); 1.49-
1.57 (br t, 2H); 2.00-2.07 (m, 1H); 2.12-2.22
(m, 4H); 2.70 (d, J=7.15 Hz, 2H); 2.80-2.85
580.18
N F (br d, 2H); 2.90 (s, 2H); 3.55 (s, 2H); 6.83 (t,
J=7.40 Hz, 2H); 7.11-7.19 (m, 1H); 7.38 (d,
J=8.00 Hz, 1H); 7.44 (d, J=8.00 Hz, 2H);
8.01 (dd, J =7.90 Hz, J2=1.40 Hz, 1H); 8.07
(d, J=8.00 Hz, 2H); 8.20 (s, 1H) Three
exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm)
0.89 (d, J=6.65 Hz, 6H); 0.97 (d, J=6.60 Hz,
6H); 1.30 (s, 9H); 1.46 (d, J=5.85 Hz, 2H);
1.48-1.56 (m, 2H); 1.68-1.77 (m, 1H); 2.00-
2.09 (m, 1H); 2.12-2.09 (br d, 2H); 2.27-2.35
510.28
(br t, 2H); 2.71 (d, J=7.20 Hz, 2H); 2.75-2.81
(br d, 2H); 3.61 (s, 2H); 7.39 (d, J=8.00 Hz,
1H); 7.49 (d, J=8.15 Hz, 2H); 8.02 (dd,
J =7.95 Hz, J =1.60 Hz, 1H); 8.11 (d, J=8.10
Hz, 2H); 8.21 (d, J=1.45 Hz, 1H) Three
exchangeable protons
Ex. MS
Structure NMR data
No. (ES+)
as t-butyl amine salt
PMR : (CDCl3 +CD3OD+TFA; 500.13 MHz ;
d ppm) 0.94 (d, J=6.80 Hz, 6H); 0.97 (d,
J=6.60 Hz, 6H); 1.43 (s, 9H); 1.83-1.92 (m,
1H); 1.95-2.10 (m, 3H); 2.33 (d, J=14.25 Hz,
496.28
2H); 2.72 (d, J=7.20 Hz, 2H); 2.83-2.94 (br t,
N OH
2H); 3.57-3.64 (br d, 2H); 4.29 (s, 2H); 7.40
(d, J=8.00 Hz, 1H); 7.62-7.66 (br d, 2H); 8.01
(dd, J1=7.95 Hz, J2=1.55 Hz, 1H); 8.20-8.24
(br m, 3H) Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl +CD OD+TFA; 500.13 MHz ;
d ppm) 0.98 (d, J=6.60 Hz, 6H); 1.42 (s, 9H);
1.96-2.10 (m, 3H); 2.31 (d, J=14.50 Hz, 2H);
N OH 2.71 (d, J=7.20 Hz, 2H); 2.85 (t, J=12.25 Hz,
612.20
2H); 2.98 (s, 2H); 3.59-3.65 (br d, 2H); 4.26
(s, 2H); 7.26-7.33 (m, 1H); 7.35-7.37 (br s,
1H); 7.38-7.44 (m, 2H); 7.51-7.56 (br d, 3H);
8.02 (dd, J =7.90 Hz, J =1.25 Hz, 1H); 8.20-
8.25 (br d, 3H) Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.60 Hz, 6H); 1.26 (s, 9H); 1.54-
1.62 (br t, 2H); 2.00-2.08 (m, 1H); 2.08-2.14
(br d, 2H); 2.27-2.36 (br t, 2H); 2.71 (d,
J=7.25 Hz, 2H); 2.73-2.79 (br d, 2H); 2.87 (s,
534.14
39 N
2H); 3.38 (s, 2H); 6.04 (d, J=3.05 Hz, 1H);
6.23-6.27 (m, 1H); 7.27 (d, J=0.95 Hz, 1H);
7.38 (d, J=7.95 Hz, 1H); 7.47 (d, J=8.10 Hz,
2H); 8.02 (dd, J =7.95 Hz, J =1.55 Hz, 1H);
8.09 (d, J=8.15 Hz, 2H), 8.21 (d, J=1.30 Hz,
1H) Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.50 Hz, 6H); 1.27 (s, 9H); 1.54-
1.62 (br t, 2H); 2.00-2.08 (m, 1H); 2.08-2.14
(br d, 2H); 2.29-2.38 (br t, 2H); 2.70 (d,
J=7.25 Hz, 2H); 2.75-2.83 (br d, 2H); 3.00 (s,
545.13 2H); 3.61 (s, 2H); 7.14-7.19 (m, 1H); 7.23 (d,
N OH
J=7.80 Hz, 1H); 7.38 (d, J=7.95 Hz, 1H);
7.46 (d, J=8.10 Hz, 2H); 7.62 (dt, J1=7.75 Hs,
J2=1.45 Hz, 1H); 8.01 (dd, J1=7.85 Hz,
J2=1.30 Hz, 1H); 8.09 (d, J=8.15 Hz, 2H),
8.20-8.22 (br s, 1H); 8.39-8.42 (br d, 1H)
Three exchangeable protons
Ex. MS
Structure NMR data
No. (ES+)
as t-butyl amine salt
PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.60 Hz, 6H); 1.28 (s, 9H); 1.56-
1.66 (br m, 2H); 2.00-2.10 (m, 3H); 2.16-2.23
(br d, 2H); 2.29-2.37 (br t, 2H); 2.71 (d,
N OH
J=7.25 Hz, 2H); 2.74-2.82 (br d, 2H); 3.61 (s,
604.12
41 O
2H); 3.83 (s, 3H); 4.08 (t, J=7.65 Hz, 2H);
6.84-6.92 (m, 4H); 7.38 (d, J=7.95 Hz, 1H);
7.48 (d, J=8.05 Hz, 2H); 8.01 (dd, J1=7.90
Hz, J2=1.10 Hz, 1H); 8.10 (d, J=8.05 Hz, 2H);
8.20 (d, J=1.00 Hz, 1H) Three exchangeable
protons
as t-butyl amine salt
PMR : (Pyridine-d ; 500.13 MHz ; d ppm)
0.90 (d, J=6.60 Hz, 6H); 1.23 (s, 9H); 1.72-
1.81 (m, 2H); 1.92-2.02 (m, 1H); 2.39-2.51
(br m, 4H); 2.62 (d, J=7.25 Hz, 2H); 2.81-
2.89 (br m, 2H); 3.05 (s, 2H); 3.53 (s, 2H);
545.16
N OH
7.17-7.21 (m, 1H); 7.36 (d, J=7.95 Hz, 1H);
7.64 (d, J=8.05 Hz, 2H); 7.67-7.70 (br d, 1H);
N 8.08 (dd, J1=7.95 Hz, J2=1.65 Hz, 1H); 8.32
(d, J=1.60 Hz, 1H); 8.40 (d, J=8.05 Hz, 2H);
8.61-8.64 (br m, 1H); 8.82-8.85 (br d, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (Pyridine-d ; 500.13 MHz ; d ppm)
0.90 (d, J=6.65 Hz, 6H); 1.21 (s, 9H); 1.72-
1.81 (m, 2H); 1.92-2.02 (m, 1H); 2.39-2.47
(br d, 2H); 2.49 (t, J=11.10 Hz, 2H); 2.62 (d,
OH J=7.25 Hz, 2H); 2.82-2.89 (br m, 2H); 3.04
545.14
(s, 2H); 3.54 (s, 2H); 7.32 (d, J=5.80 Hz, 2H);
7.37 (d, J=8.00 Hz, 1H); 7.65 (d, J=8.05 Hz,
2H); 8.08 (dd, J1=7.85 Hz, J2=1.50 Hz, 1H);
8.32 (d, J=1.45 Hz, 1H); 8.40 (d, J=8.00 Hz,
2H); 8.67 (d, J=5.70 Hz, 2H); Three
exchangeable protons
as t-butyl amine salt
PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
NH 3 3
1.18 (s, 3H); 1.26 (s, 9H); 1.45 (d, J=6.05
Hz, 6H); 1.47-1.53 (br m, 2H); 2.09-2.16 (br
470.11
d, 2H); 2.27-2.36 (br t, 2H); 2.68-2.76 (br d,
44 N
2H); 3.60 (s, 2H); 4.74 (quintet, J=6.10 Hz,
1H); 7.09 (d, J=8.80 Hz, 1H); 7.47 (d, J=8.10
Hz, 2H); 8.06-8.12 (m, 3H); 8.23 (d, J=2.00
Hz, 1H); Three exchangeable protons
Ex. MS
Structure NMR data
No. (ES+)
as t-butyl amine salt
PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
2 3 3
1.16 (s, 3H); 1.28 (s, 9H); 1.46-1.54 (m, 2H);
1.54 (s, 9H); 2.08-2.16 (br d, 2H); 2.30-2.38
468.11
(br t, 2H); 2.70-2.77 (br s, 2H); 3.63 (s, 2H);
45 N OH
7.49 (d, J=8.15 Hz, 2H); 7.63 (d, J=8.35 Hz,
1H); 8.02 (dd, J =8.30 Hz, J =1.75 Hz, 1H);
8.11 (d, J=8.05 Hz, 2H); 8.19 (d, J=1.80 Hz,
1H) Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 200.13 MHz ; d ppm)
1.02 (t, J=7.26 Hz, 3H); 1.17 (s, 3H); 1.27 (s,
9H); 1.40-1.58 (br m, 2H); 1.61-1.81 (m, 2H);
2.03-2.19 (br d, 2H); 2.23-2.40 (br t, 2H);
454.12
2.62-2.87 (br m, 4H); 3.61 (s, 2H); 7.42 (d,
N OH
J=8.08 Hz, 1H); 7.48 (d, J=8.26 Hz, 2H);
8.02 (d, J1=7.94 Hz J2=1.72 Hz, 1H); 8.10 (d,
J=8.20 Hz, 2H); 8.20 (d, J=1.68 Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD+D2O; 200.13 MHz ;
d ppm) 1.29 (s, 9H); 1.45 (d, J=6.02 Hz, 6H);
1.50-1.63 (br d, 2H); 2.06-2.21 (br d, 2H);
2.28-2.44 (br t, 2H); 2.63-2.79 (br d, 2H);
544.15
N OH 3.35 (s, 3H); 3.44-3.62 (two singlets merged
in triplet, 8H); 4.73 (septate, J=6.08 Hz, 1H);
7.08 (d, J=8.84 Hz, 1H); 7.48 (d, J=8.16 Hz,
2H); 8.02-8.13 (m, 3H); 8.22 (d, J=2.10 Hz,
1H);
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 200.13 MHz ; d ppm)
0.85 (t, J=7.32 Hz, 3H); 1.26 (s, 9H); 1.43 (d,
J=6.02 Hz, 6H); 1.49-1.61 (m, 4H); 2.03-2.20
(br d, 2H); 2.20-2.36 (br t, 2H); 2.70-2.86 (br
484.16
d, 2H); 3.60 (s, 2H); 4.74 (pentate, J=5.92
Hz, 1H); 7.09 (d, J=8.74 Hz, 1H); 7.47 (d,
J=8.16 Hz, 2H); 8.03-8.13 (m, 3H); 8.23 (d,
J=2.10 Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl +CD OD; 200.13 MHz ; d ppm)
Cl 3 3
O 1.26 (s, 9H); 1.45 (d, J=6.04 Hz, 6H); 1.49-
496.12
1.62 (br d, 2H); 2.03-2.18 (br d, 2H); 2.23-
N OH
2.39 (br m, 4H); 2.71-2.83 (br m, 2H); 3.62
(s, 2H); 4.72 (pentate, J=6.10 Hz, 1H); 4.95-
.01 (br s, 1H); 5.01-5.10 (br d, 1H); 5.66-
Ex. MS
Structure NMR data
No. (ES+)
.90 (m, 1H); 7.06 (d, J=8.90 Hz, 1H); 7.48
(d, J=8.24 Hz, 2H); 8.01-8.13 (m, 3H); 8.22
(d, J=2.14 Hz, 1H);
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 200.13 MHz ; d ppm)
1.28 (s, 9H); 1.50-1.69 (br m, 2H); 2.01-2.18
(br d, 2H); 2.23-2.42 (br t, 2H); 2.73-2.87 (br
d, 2H); 3. 00 (s, 2H); 3.61 (s, 2H); 7.12-7.27
565.12
N OH
(m, 2H); 7.42-7.53 (br m, 7H); 7.55 (d,
J=8.04 Hz, 1H); 7.63 (dt, J1=7.68 Hz, J2=1.82
Hz, 1H); 8.07-8.19 (m, 3H); 8.34 (d, J=1.64
Hz, 1H); 8.38-8.44 (br d, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD+TFA; 500.13 MHz ;
d ppm) 1.42 (s, 9H); 1.84-1.94 (br t, 2H);
2.33-2.40 (br d, 2H); 2.87 (s, 2H); 2.94-3.02
(br t, 2H); 3.57-3.63 (br d, 2H); 3.80 (s, 3H);
OH 4.30 (s, 3H); 6.83 (d, J=8.50 Hz, 2H); 7.01
594.12
(d, J=8.50 Hz, 2H); 7.44-7.50 (m, 1H); 7.50-
7.54 (m, 3H); 7.56 (d, J=8.10 Hz, 2H); 7.60
(d, J=8.00 Hz, 1H); 8.17 (dd, J1=8.05 Hz,
J =1.40 Hz, 1H); 8.23 (d. J=8.15 Hz, 2H);
8.35 (d, J=1.40 Hz, 1H) Three exchangeable
protons
as t-butyl amine salt
PMR : (CDCl +CD OD; 400.13 MHz ; d ppm)
1.18 (s, 9H); 1.42-1.52 (br t, 2H); 1.98 (d,
J=13.14 Hz, 2H); 2.18-2.28 (br t, 2H); 2.68-
N OH
582.08
2.78 (s merged in m, 4H); 3.52 (s, 2H); 6.83
(t, J=8.61 Hz, 2H); 7.00-7.07 (m, 2H); 7.34-
7.45 (m, 7H); 7.47 (d, J=8.01 Hz, 1H); 8.03
(d, J=7.99 Hz, 2H); 8.07 (d, J=8.58 Hz, 1H);
8.26 (s, 1H) Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD+TFA; 400.13 MHz ;
2 d ppm) 1.25-1.55 (s merged in m, 15H); 1.78-
1.97 (m, 6H); 2.27 (d, J=14.32 Hz, 2H); 2.81-
2.91 (s merged in m, 4H); 3.07-3.16 (br t,
600.12
N OH
1H); 3.49-3.56 (br d, 2H); 3.77 (s, 3H); 4.23
(s, 2H); 6.79 (d, J=8.37 Hz, 2H); 7.48 (d,
J=8.17 Hz, 1H); 7.54 (d, J=8.03 Hz, 2H);
8.05 (d, J=8.03 Hz, 1H); 8.19-8.25 (s merged
in d, 3H) Two protons are merged between
6.94-7.03 Three exchangeable protons
Ex. MS
Structure NMR data
No. (ES+)
as t-butyl amine salt
PMR : (Pyridine-d5; 400.13 MHz ; d ppm)
1.01 (t, J=7.38 Hz, 3H); 1.17 (s, 9H); 1.27-
1.43 (br m, 5H); 1.60-1.71 (br m, 3H) 1.71-
508.07 1.80 (br m, 5H); 1.80-1.86 (br d, 2H); 2.42-
54 N OH
2.52 (br t, 2H); 2.78-2.87 (br d, 2H); 3.03-
3.12 (br t, 1H); 3.53 (s, 2H); 7.47 (d, J=8.13
Hz, 1H); 7.65 (d, J=7.92 Hz, 2H); 8.14 (d,
J=8.10 Hz, 1H); 8.32 (s, 1H); 8.39 (d, J=8.00
Hz, 2H) Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl +CD OD; 500.13 MHz ; d ppm)
1.26 (s, 9H); 1.53-1.61 (br t, 2H); 2.05-2.12
(br d, 2H); 2.22-2.29 (br t, 2H); 2.76-2.83 (br
564.12 d, 2H); 2.84 (s, 2H); 3.58 (s, 2H); 7.13-7.20
N OH
(m, 3H); 7.20-7.25 (m, 2H); 7.43-7.53 (m,
7H); 7.56 (d, J=8.00 Hz, 1H); 8.11 (d, J=8.05
Hz, 2H); 8.16 (dd, J1=7.95 Hz, J2=1.45 Hz,
1H); 8.34 (d, J=1.30 Hz, 1H) Three
exchangeable protons
as t-butyl amine salt
PMR : (Pyridine-d5; 400.13 MHz ; d ppm)
1.18 (s, 9H); 1.27-1.40 (br m, 5H); 1.63-1.71
(br d, 1H); 1.71-1.87 (br m, 4H); 1.91-2.12
(br t, 2H); 2.48-2.58 (br t, 4H); 2.82-2.92 (br
N OH
571.15 d, 2H); 3.03-3.12 (br t, 1H); 3.39 (s, 2H); 3.53
ON (s, 2H); 7.04-7.10 (m, 1H); 7.35 (d, J=7.71
Hz, 1H); 7.47 (d, J=8.17 Hz, 1H); 7.52 (t,
J=7.63 Hz, 1H); 7.62 (d, J=7.95 Hz, 2H);
8.15 (d, J=7.19 Hz, 1H); 8.32 (d, J=1.12 Hz,
1H); 8.37 (d, J=8.00 Hz, 2H); 8.65 (d, J=3.80
Hz, 1H) Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 400.13 MHz ; d ppm)
1.26 (s, 9H); 1.45 (d, J=6.00 Hz, 6H); 1.53-
1.61 (m, 2H); 2.10-2.17 (br d, 2H); 2.35 (t,
N OH
500.12 J=10.90 Hz, 2H); 2.72-2.81 (br d, 2H); 3.31
(s, 3H); 3.40 (s, 2H); 3.62 (s, 2H); 4.75
(septate, J=6.10 Hz, 1H); 7.10 (d, J=8.85 Hz,
1H); 7.48 (d, J=8.20 Hz, 2H); 8.06-8.12 (m,
3H); 8.23 (d, J=1.95 Hz, 1H) Three
exchangeable protons
Ex. MS
Structure NMR data
No. (ES+)
as t-butyl amine salt
PMR : (Pyridine-d ; 500.13 MHz ; d ppm)
1.15 (s, 9H); 1.77 (t, J=10.85 Hz, 2H); 2.40-
2.47 (br m, 4H); 2.84-2.87 (br d, 2H); 3.04 (s,
2H); 3.53 (s, 2H); 7.18-7.20 (br m,1H); 7.45-
565.11
7.60 (br m ,6H); 7.64-7.68 (br m, 3H); 8.20
(dd, J =7.95 Hz, J = 1.7 Hz, 1H); 8.41-8.45
N (br m, 3H); 8.63 (dd, J1=4.75 Hz, J2= 1.55
Hz, 1H); 8.83 (d, J=1.75 Hz, 1H) Three
exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.60 Hz, 6H); 1.19 (t, J=7.05 Hz,
2 3H); 1.29 (s, 9H); 1.53-1.62 (br t, 2H); 2.00-
2.10 (m, 1H); 2.10-2.16 (br d, 2H); 2.36 (t,
J=10.85 Hz, 2H); 2.71 (d, J=7.25 Hz, 2H);
N OH 556.18
2.73-2.80 (br d, 2H); 3.48 (s, 2H); 3.53 (q,
ON O
J=7.05 Hz, 2H); 3.55-3.58 (br s, 4H); 3.62 (s,
2H); 7.39 (d, J=8.00 Hz, 1H); 7.49 (d, J=8.05
Hz, 2H); 8.02 (d, J=7.95 Hz, 1H); 8.10 (d,
J=8.10 Hz, 2H); 8.21 (d, J=1.10 Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 400.13 MHz ; d ppm)
NH 0.97 (d, J=6.64 Hz, 6H); 1.10 (d, J=6.08 Hz,
6H); 1.27 (s, 9H); 1.56-1.66 (br m, 2H); 1.99-
2.08 (m, 1H); 2.07-2.14 (br d, 2H); 2.30-2.39
N OH (br t, 2H); 2.71 (d, J=7.20 Hz, 2H); 2.73-2.80
526.18
(br d, 2H); 3.38 (pentate, J=1.64 Hz, 1H);
ON O
3.44 (s, 2H); 3.61 (s, 2H); 7.38 (d, J=8.00
Hz, 1H); 7.48 (d, J=8.24 Hz, 2H); 8.02 (dd,
J1=7.92 Hz, J2=1.72 Hz, 1H); 8.10 (d, J=8.24
Hz, 2H); 8.21 (d, J=1.68 Hz, 1H) Three
exchangeable protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.60 Hz, 6H); 1.27 (s, 9H); 1.44-
1.50 (br m, 2H); 1.57-1.69 (br m, 8H); 1.99-
2.07 (m, 1H); 2.07-2.13 (br d, 2H); 2.32-2.39
OH (br t, 2H); 2.70 (d, J=7.20 Hz, 2H); 2.72-2.79
552.17
(br m, 2H); 3.40 (s, 2H); 3.62 (s, 2H); 3.81-
3.86 (br m, 1H); 7.37 (d, J=8.00 Hz, 1H);
7.48 (d, J=8.20 Hz, 2H); 8.01 (dd, J =7.95
Hz, J2=1.65 Hz, 1H); 8.10 (d, J=8.15 Hz, 2H);
8.21 (d, J=1.55 Hz, 1H) Three exchangeable
protons
Ex. MS
Structure NMR data
No. (ES+)
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm)
0.97 (d, J=6.60 Hz, 6H); 1.28 (s, 9H); 1.56-
1.64 (br m, 2H); 2.05 (septate, J=6.75 Hz,
1H); 2.09-2.16 (br d, 2H); 2.33-2.42 (br t,
2H); 2.71 (d, J=7.25 Hz, 2H); 2.75-2.82 (br d,
550.11
62 OH
2H); 3.14 (s, 2H); 3.62 (s, 2H); 6.81 (d,
J=3.35 Hz, 1H); 6.89 (t, J=3.65 Hz, 1H); 7.10
(d, J=5.25 Hz, 1H); 7.39 (d, J=8.00 Hz, 1H);
7.48 (d, J=8.10 Hz, 2H); 8.02 (dd, J1=7.95
Hz, J2=1.45 Hz, 1H); 8.10 (d, J=8.05 Hz, 2H);
8.20 (d, J=1.30 Hz, 1H) Three exchangeable
protons
as t-butyl amine salt
PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm)
0.01-0.06 (br m, 2H); 0.38-0.44 (br m, 2H);
0.64-0.73 (br m, 1H); 0.97 (d, J=6.65 Hz,
O 6H); 1.28 (s, 9H); 1.44 (d, J=6.70 Hz, 2H);
1.53-1.62 (br t, 2H); 2.05 (septate, J= 6.85
508.18
Hz, 1H); 2.17-2.24 (br d, 2H); 2.27-2.37 (br t,
2H); 2.71 (d, J=7.20 Hz, 2H); 2.78-2.85 (br d,
2H); 3.63 (s, 2H); 7.40 (d, J=6.50 Hz, 1H);
7.49 (d, J=8.15 Hz, 2H); 8.02 (dd, J1=7.90
Hz, J2=1.65 Hz, 1H); 8.10 (d, J=8.10 Hz, 2H);
8.20 (d, J=1.60 Hz, 1H) Three exchangeable
protons
as free form
PMR : (CDCl +CD OD+D O; 500.13 MHz ;
3 3 2
d ppm) 0.97 (d, J=6.65 Hz, 6H); 1.45-1.53 (br
dt, 2H); 1.77 (t, J=7.35 Hz, 2H); 2.04
(septate, J=6.75 Hz, 1H); 2.10-2.16 (br d,
567.16 2H); 2.27 (t, J=10.70 Hz, 2H); 2.61 (t, J=7.30
Hz, 2H); 2.66-2.75 (br d merged with m, 8H);
3.57 (s, 2H); 3.74-3.80 (br t, 4H); 7.36 (d,
J=8.00 Hz, 1H); 7.46 (d, J=8.05 Hz, 2H);
8.01 (dd, J1=7.94 Hz, J2=1.55 Hz, 1H); 8.10
(d, J=8.15 Hz, 2H); 8.21 (d, J=1.55 Hz, 1H)
One exchangeable protons
as t-butyl amine salt
PMR : (CDCl3; 400.13 MHz ; d ppm) 0.96 (d,
N OH
J=6.64 Hz, 6H); 1.21 (s, 9H); 1.32-1.43 (br
ON 579.18
m, 4H); 1.60-1.76 (br m, 8H); 2.04 (septate,
NH J=6.84 Hz, 1H); 2.14-2.24 (br m, 8H); 2.61-
2.68 (br m, 2H); 2.70 (d, J=7.20 Hz, 2H);
2.72-2.79 (br m, 2H); 3.58 (s, 2H); 7.36 (d,
Ex. MS
Structure NMR data
No. (ES+)
J=8.00 Hz, 1H); 7.44 (d, J=8.24 Hz, 2H);
8.01 (dd, J1=7.96 Hz, J2=1.76 Hz, 1H); 8.08
(d, J=8.28 Hz, 2H); 8.20 (d, J=1.72 Hz, 1H)
Three exchangeable protons
as t-butyl amine salt
PMR : (CDCl3; 400.13 MHz ; d ppm) 0.96 (d,
J=6.64 Hz, 6H); 1.20 (s, 9H); 1.30-1.41 (br
m, 4H); 1.59-1.70 (br m, 2H); 1.83-1.91 (br s,
6H); 1.98-2.09 (m, 1H); 2.09-2.20 (br m, 6H);
565.23
2.70 (d, J=7.20 Hz, 2H); 2.71-2.83 (m, 4H);
3.57 (s, 2H); 7.36 (d, J=8.00 Hz, 1H); 7.43
(d, J=8.20 Hz, 2H); 8.01 (dd, J1=7.92 Hz,
J =1.68 Hz, 1H); 8.07 (d, J=8.20 Hz, 2H);
8.21 (d, J=1.64 Hz, 1H) Three exchangeable
protons
Biological activity
Some of the representative compounds of the present invention were tested for in-
vitro and in-vivo efficacy as mentioned below.
a) 35S-GTP γS Binding Assay
GTP- γ- S binding was performed using 5 µg protein of cell membranes suspended
in 50 mM tris-HCl pH 7.5 containing 10 mM MgCl , 100 mM NaCl and 10 µM GDP. The
radioligand was 0.025 nM [ S] GTP- γ-S and non specific binding determined in the presence
of 10 µM non-radioactive GTP- γ-S. Agonists of S1P receptors can be discriminated in the
[ S] GTP- γ-S binding assay. S1P and receptor agonists enhance the specific binding
whereas inverse agonists reduce it. The maximal stimulation elicited by S1P was taken as a
reference to define full or partial agonism and calculate the intrinsic activity (i.a.) of
compounds.
Typical results shown in Table 1a indicate that compounds of the invention are able to
activate S1P1 receptors with a potency similar to that of S1P itself (i.e. with full intrinsic
activity and at nanomolar concentrations) without affecting significantly S1P2 and S1P3
receptors.
Table 1b summarizes the half maximal effective concentration (EC50) for the
examples of the present application.
Furthermore, we settled a binding assay on HEK293-EDG-1 cells on these
membranes using [3H]dihydroS1P. By Scatchard analysis we identified one binding site for
[3H]dihydroS1P. Both S1P and dihydroS1P (an S1P biometabolite) compete with
[3H]dihydroS1P on transfected HEK293 cells with an IC50 closed to 5 ± nM and a maximum
binding capacity Bmax of 13 pmol/mg of protein.
b) Assessment of lymphopenia
Lymphopenia was assessed in vivo. Experiments were done in non-fasted/fasted
Swiss mice and/or: Sprague Dawley rats, Wistar rats, Beagle dogs, Cynomolgus monkeys.
Compounds were administered orally in suspension in carboxymethyl-cellulose 0.5-1% in
water (W/V). Blood was taken on anesthetized/non anaesthetized animal (4% isoflurane) and
samples collected in EDTA-containing vacuum tubes from 1h30 to 72 hours post
administration for lymphopenia measurement.
After 10 minutes stirring, cells were counted using ABC Vet haemocytometer (Scil vet
animal Care) for rodent and dog or ADVIA 120 hematology analyzer for monkeys.
Pharmacodynamic effect was measured by the decrease in circulating lymphocytes by test
item treatment in comparison with haematological parameters of control animals or versus
predosing in the same animals.
c) Evaluation of activityfor hERG blockade liability
HEK293 cells were stably transfected with the human hERG receptor gene. Binding
assays were performed using 5 µg of cell membranes expressing hERG channel
resuspended in 10mM Hepes pH 7.4, 135 mM NaCl, 60 mM DL-Aspartic Acid Potassium, 1
mM EGTA, 0.8 mM MgCl , 10 mM (D+) Glucose, 0.01 % BSA, in a final volume of 200 µL.
For [ H] Dofetilide binding, the incubation volume was 200 µL and incubation was performed
60 minutes at room temperature under continuous stirring. Non specific binding was
estimated in the presence of 1 µM Astemizole. The reaction was terminated by filtration
through Durapore BV 1.2 µm filters pre-soaked in 3 % polyethyleneimine 10 minutes at room
temperature. Filters were rinsed 2 times with 250 µL of ice cold 25 mM Tris-HCl pH 7.4
buffer. The filter-bound radioactivity was measured in a liquid scintillation counter with 50 µL
of scintillation fluid. [ H] Dofetilide was used at concentrations in the range of 5 nM.
The hERG binding investigated by use of [ H] Dofetilide gives a Bmax = 3.09
pmoles/mg protein and a Kd = 4.24 nM.
No binding was detectable in wild type HEK293 cell membranes.
Tables 1 (Table 1a and 1b) and 2 show the results of the in vitro and the in vivo tests
on some of the representative compounds of the present invention.
Table 1: in vitro evaluation
Table 1a:
EC50 (nM) hERG
Structure (dofetilide)
No. EDG1 EDG3 EDG5
Ki (µM)
<1 >1000 >1000 >10
N OH
N OH
<1 - - >10
<1 581 >1000 >10
<1 >1000 >1000 >10
N OH
<1 610 - >10
N OH
O N O
<1 198 >1000 >10
N OH
<1 >1000 >1000 >10
EC50 (nM) hERG
Structure (dofetilide)
EDG1 EDG3 EDG5
Ki (µM)
<1 >1000 >1000 >10
N OH
<1 >1000 >1000 >10
N OH
N OH <1 >1000 >1000 >10
Table 1b :
EDG1 EDG1 EDG1 EDG1 EDG1
Ex Ex Ex Ex Ex
EC50 EC50 EC50 EC50 EC50
1 <1 2 <1 4 <1 5 <1 6 <1
7 <1 8 <1 9 <1 10 <1 11 <1
12 <1 13 <1 14 <1 15 <1 16 <1
17 <1 18 <1 19 <1 20 <1 21 <1
22 <1 23 <10 24 <10 25 <1 26 <1
27 <1 28 <1 29 <1 30 <1 31 <10
32 <1 33 <1 34 <1 35 <1 36 <10
37 <1 38 <10 39 <10 40 <1 41 <1
42 <1 43 <1 44 <10 45 <10 46 <1
47 <1 48 <10 49 <1 50 <1 51 <1
52 <1 53 <1 54 <1 55 <1 56 <1
57 <10 58 <1 59 <1 60 <1 61 <1
62 <1 63 <1 64 <10 65 <10 66 <10
Table 2: in vivo evaluation
Lymphopenia in rats
Ex. No. Structure % lymphopenia at given dose at Species
24hrs
N OH
76% (0.3mpk) SD F
75% (0.3 mpk) W F
N OH
66% (0.3 mpk) W F
N OH
72% (0.3 mpk) W M
O N O
69% (0.3mpk) SD F
N OH
ON OH
W: Wistar SD: Sprague-Dawley M: male F: female
The results above show that the compounds of the present invention are S1P
agonists and have high affinity for human EDG1 receptors (EC50 ≤ about 2 nM). More
preferred compounds of the invention have EC50 less than 1 nM. The compounds of the
present invention possess about 500 fold selectivity for EDG1 receptors over EDG3 receptor.
Furthermore, the compounds of present invention have about 400 fold selectivity for EDG1
receptor over hERG channel and hence are expected to demonstrate a better side effect
profile.
The preferred compounds of the present invention were found to exhibit lymphopenic
activity in-vivo when administered orally to animal models. More preferably, the compounds
of the invention exhibited lymphopenic activity of more than 50% at 8 hours and did not bind
to hERG channel, even at a concentration as high as 5µM.
Most preferably, the compounds of the invention which possessed EC50 of less than
1nM, have >1000 fold selectivity for EDG1 receptor over EDG3, exhibited in-vivo
lymphopenic activity of more than 50% at 24 hours and did not bind to hERG even at a
concentration as high as 10µM.
Comparative examples:
The table below shows that the WO2008/152149 monosubstituted carboxylate
derivatives are poorly active in vitro as agonist on the human EDG1 receptor and ineffective
in producing lymphopenia in rat model.
Lymphopenia in rats
EDG1
% lymphopenia at 1
Comparative compounds EC50
mpk/p.o dose
(nM)
8 Hrs 24 Hrs
N OH
1 11.7-19.8 -54%
O N O
Example XXVIII of WO2008/152149
N OH
2 57.2 -25% -101%
O N O
Example XXXI of WO2008/152149
N COOH
CH N
3 56.6 -58%
-24%
Example XIL of WO2008/152149
N OH
4 13.9 -57%
O N O
Example XXXVI of WO2008/152149
Moreover, preferred compounds of the present invention also display an outstanding
bioavailability. Comparison with a compound of WO2003105771 is shown in the following
table:
Pharmacokinetic parameters in
Swiss mice after oral
administration (1 mg/kg p.o.)
Structure
(n=4)
Cmax AUC(0-48h)
(ng/mL) (ng/mL*h)
Comparative
compound 5
495 4530
Example 1 of WO2003105771
Example 3
798 13111
N OH
Example 14
N 843 9241
O N O
It appears from the in vivo ED50 values below that the representative disubstituted
monocarboxylate derivatives of the present invention exhibit improved in vivo lymphopenia
activity over their corresponding dicarboxylate counterparts disclosed in :
ED50 (EDG1)
(In mice)
Example 8 O 0.1 mg/kg
CO H
Comparative 0.4 mg/kg
example 6 F
N OH
ON O OH
Example 3 of
Example 3 0.2 mg/kg
CO H
Example 14 0.2 mg/kg
N OH
O N O
Comparative 1.8 mg/kg
example 7
N OH
ON O OH
Example 1 of
Example 10 0.2 mg/kg
N OH
O N O
Comparative 10 mg/kg
example 8
N OH
ON O OH
Example 37 of
The compounds of the invention show a better in vivo activity profile over their
corresponding counterparts of , as evidenced below :
ED50 (EDG1)
Compound of the 40% at 1 mg/kg
invention
ON O OH
Comparative Inactive at 1
example 9 mg/kg
Example 7 of
In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
providing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission that
such documents, or such sources of information, in any jurisdiction, are prior art, or form part of
the common general knowledge in the art.
In the description in this specification reference may be made to subject matter that is
not within the scope of the claims of the current application. That subject matter should be
readily identifiable by a person skilled in the art and may assist in putting into practice the
invention as defined in the claims of this application.
Claims (23)
1. A compound of formula (I): N R2 COOH wherein: Ar is an aryl group optionally substituted by one or more identical or different group(s) selected from halogen, alkyl, cycloalkyl, -Oalkyl, aryl wherein the alkyl, cycloalkyl, -Oalkyl, aryl may be further substituted with halogen, OH, Oalkyl, CN, NH , NHalkyl, N(alkyl) or alkyl; R1 represents –X-(Y) Where -X- is selected from –alkyl-, -alkenyl-, -alkynyl-, -aryl-, -alkylaryl-, Each Y, identical or different is selected from H, OH, halogen, -Oalkyl, -Oalkylaryl, -OalkylOalkyl, -Oaryl, heteroaryl, -Oaryl(Oalkyl), -Ocycloalkyl, -cycloalkyl, heterocyclyl; n is 1 to 3; R2 is selected from H, alkyl; or one of its stereoisomers, salts or esters thereof.
2. The compound according to claim 1, wherein Ar is a disubstituted phenyl group.
3. The compound according to claim 1 or 2 of formula (II): COOH (II) wherein : R1 is defined as in claim 1 ; R3 is selected from halogen, aryl, cycloalkyl, alkyl, and -Oalkyl ; Hal represents a halogen atom.
4. The compound according to any one of the preceding claims, wherein R1 is selected from: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, secondarybutyl, tertiary butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxymethyl, ethoxymethyl, methoxyethyl, vinyl, allyl, methoxyethoxymethyl, ethoxyethoxymethyl, ethoxyethoxyethyl, Phenyl, benzyl, benzyloxymethyl, benzyloxyethyl, -CH -[Ph(o-F)], -CH -[Ph(m-F)], -CH -[Ph(p-F)], -CH -[Ph(o-OMe)], -CH -[Ph(m-OMe)], or 2 2 2 2 2 -CH -[Ph(p-OMe)], methoxybutyl, methoxyethoxymethyl, methoxyethoxyethyl, -CH -[Ph(o,o- F)], -CH -[Ph(m-CF)], -CH-furyl, -CH-pyridyl, (2-methoxy-phenoxy)-ethyl, 4-methoxy- 2 2 3 2 2 benzyl, isopropoxy methyl, cyclopentyloxymethyl, thiophenylmethyl, cyclopropylmethyl, 2-morpholinyl-ethyl, 3-piperidinyl-propyl, 3-pyrrolidinyl-propyl.
5. The compound according to any one of the preceding claims, wherein R2 is H.
6. The compound according to any one of the preceding claims, wherein R3 is selected from phenyl, cyclohexyl, cyclopentyl, isobutyl, , isopropoxy.
7. The compound according to any one of the preceding claims which is selected from: 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}ethylpiperidine carboxylic acid 4-allyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}piperidine carboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}propylpiperidine carboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} hydroxymethylpiperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]oxadiazolyl]-benzyl} methoxymethylpiperidinecarboxylic acid 4-Allyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidine carboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}propylpiperidine carboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid 4-Benzyloxymethyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid 4-Benzyloxymethyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl} hydroxymethylpiperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}phenylpiperidine- 4-carboxylic acid 4-Benzyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}-piperidine- 4-carboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(4-fluoro-benzyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-fluoro-benzyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(4-methoxy- benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-methoxy- benzyl)-piperidinecarboxylic acid 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}ethylpiperidine carboxylic acid 1-{4-[5-(4-Isobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine carboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy- butyl)-piperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-phenoxy- ethyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2,6-difluoro- benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isobutyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(3-trifluoro methyl-benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}furanylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}[2-(2-methoxy- phenoxy)-ethyl]-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl- piperidinecarboxylic acid 1-{4-[5-(4-tert-Butylchloro-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloropropyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine- 4-carboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-methoxy- ethoxymethyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl- piperidinecarboxylic acid 4-Allyl{4-[5-(3-chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}- piperidinecarboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)- piperidinecarboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-fluoro-benzyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy- benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl- piperidinecarboxylic acid 4-Benzyl{4-[5-(2-chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine carboxylic acid 1-{4-[5-(3-Chlorocyclohexyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} methoxymethyl-piperidinecarboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-ethoxy- ethoxymethyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropoxy methyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} cyclopentyloxymethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}thiophen ylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} cyclopropylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-morpholin yl-ethyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3-piperidinyl- propyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3-pyrrolidinyl- propyl)-piperidinecarboxylic acid and their pharmaceutically acceptable salts, or esters thereof.
8. The compound according to any one of the preceding claims which is selected from: 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, sodium salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, arginine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, potassium salt 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid, tert-butylamine salt 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}ethylpiperidine carboxylic acid tert-butylamine salt 4-allyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}piperidine carboxylic acidtert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}propylpiperidine carboxylic acid tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} hydroxymethylpiperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]oxadiazolyl]-benzyl} methoxymethylpiperidinecarboxylic acid tert-butylamine salt 4-Allyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidine carboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}propylpiperidine carboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid tert-butylamine salt 4-Benzyloxymethyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid tert-butylamine salt 4-Benzyloxymethyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl} hydroxymethylpiperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}phenylpiperidine- 4-carboxylic acid tert-butylamine salt 4-Benzyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}-piperidine- 4-carboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(4-fluoro-benzyl)- piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-fluoro-benzyl)- piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(4-methoxy- benzyl)-piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-methoxy- benzyl)-piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}ethoxymethylpiperidine- 4-carboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}ethylpiperidine carboxylic acid tert-butylamine salt, 1-{4-[5-(4-Isobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy- butyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid potassium salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-phenoxy- ethyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2,6-difluoro- benzyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isobutyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(3-trifluoro methyl-benzyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}furanylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}[2-(2-methoxy- phenoxy)-ethyl]-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(4-tert-Butylchloro-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloropropyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine- 4-carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-methoxy- ethoxymethyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl- piperidinecarboxylic acid tert-butyl amine salt 4-Allyl{4-[5-(3-chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-fluoro-benzyl)- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy- benzyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl- piperidinecarboxylic acid tert-butyl amine salt 4-Benzyl{4-[5-(2-chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chlorocyclohexyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} methoxymethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-ethoxy- ethoxymethyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropoxy methyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} cyclopentyloxymethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}thiophen ylmethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} cyclopropylmethyl-piperidinecarboxylic acid tert-butyl amine salt, or one of their stereoisomers.
9. A process of preparation of a compound according to any one of the preceding claims comprising saponifying a compound of formula (III) N R2 COOAlk (III) where Ar, R2, R1 are defined as any one of the preceding claims and Alk represents a C1- C6 alkyl group, optionally followed by forming the desired addition salt.
10. The process according to claim 9 which further comprises the step of preparing the compound of formula (III) by coupling a compound of formula (IV): N R2 (IV) with a corresponding compound of formula (V): COOAlk where Ar, R2, R1 are defined as in any one of claims 1 to 8, Alk is defined as in claim 9 and LG is a leaving group
11. The process according to claim 10 further comprising the step of preparing the compound of formula (IV) wherein LG is a halide or mesylate, by converting a compound of formula (VI): N R2 (VI) where Ar and R2 are defined as in any one of claims 1 to 8 into the desired halide or mesylate.
12. A process of preparation of a compound according to any one of claims 1 to 8 comprising reacting a compound of formula (VII): N R2 (VII) with a compound of formula (VIII) COOR (VIII) where Ar, R2, R1 are defined as in any one of claims 1 to 8, and R may be alkyl, optionally followed by forming the desired addition salt.
13. The process according to claim 12 further comprising the step of preparing the compound of formula (VII) by oxidizing a compound of formula (VI): N R2 (VI) where Ar and R2 are defined as in any one of claims 1 to 8.
14. The process according to claim 11 or 13 further comprising: (a) preparing the compound of formula (VI) R2 is H by reacting a compound of formula (IX): (IX) where Ar is defined as in any one of claims 1 to 8, with N-hydroxyhydroxymethylbenzamidine, optionally in the presence of one or more of activating and/or coupling agent, optionally followed by (b) oxidizing the obtained compound of formula (VI) (wherein R2 is H) followed by its reaction with alkylmagnesiumhalide.
15. The process according to any one of claims 9 to 14 further comprising the additional step of isolating the obtained compound.
16. A compound prepared by the process of any one of claims 9 to 15.
17. The compound according to any one of claims 1 to 8 and 16 for use in the treatment and/or prevention of transplant rejection, tissue graft rejection, immune disorders auto-immune diseases, autoimmune uveitis, ischemia, inflammatory and chronic inflammatory conditions that include rheumatoid arthritis, asthma, pollinosis, psoriasis, Alzheimer’s disease, myocarditis, atopic dermatitis, lymphocytic leukemias, lymphomas, sepsis, multiple sclerosis, lupus erythematosus, inflammatory bowel diseases, diabetes mellitus, glomerulonephritis, atherosclerosis, multiorgan failure, pneumonia, ischemia reperfusion injury, chronic obstructive pulmonary disease, infection associated with inflammation, viral inflammation, hepatitis, chronic bronchitis, granulomatous disease, as well as disorders related to impaired vascular integrity, cancer, or other disorders.
18. A use of a compound according to any one of claims 1 to 8 and 16 in the manufacture of a medicament for the treatment and/or prevention of transplant rejection, tissue graft rejection, immune disorders auto-immune diseases, autoimmune uveitis, ischemia, inflammatory and chronic inflammatory conditions that include rheumatoid arthritis, asthma, pollinosis, psoriasis, Alzheimer’s disease, myocarditis, atopic dermatitis, lymphocytic leukemias, lymphomas, sepsis, multiple sclerosis, lupus erythematosus, inflammatory bowel diseases, diabetes mellitus, glomerulonephritis, atherosclerosis, multiorgan failure, pneumonia, ischemia reperfusion injury, chronic obstructive pulmonary disease, infection associated with inflammation, viral inflammation, hepatitis, chronic bronchitis, granulomatous disease, as well as disorders related to impaired vascular integrity, cancer, or other disorders.
19. A combination comprising a compound according to any one of claims 1 to 8 and 16 with an immunosuppressant including adrenocortical steroids, cyclosporine, azathioprine, methotrexate, calcineurin inhibitors, IL-2 receptor blocking antibodies, T-cell and other immune cell depleting antibodies, anti-TNF, mycophenolate, mTOR inhibitors.
20. A compound as claimed in claim 1 or claim 16, substantially as herein described with reference to any example thereof.
21. A process as claimed in claim 9 or claim 12, substantially as herein described with reference to any example thereof.
22. A use as claimed in claim 18, substantially as herein described with reference to any example thereof.
23. A combination as claimed in claim 19, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305433.2 | 2011-04-12 | ||
EP11305433A EP2511275A1 (en) | 2011-04-12 | 2011-04-12 | Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists |
PCT/EP2012/056470 WO2012140020A1 (en) | 2011-04-12 | 2012-04-10 | Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ617500A NZ617500A (en) | 2016-03-31 |
NZ617500B2 true NZ617500B2 (en) | 2016-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3076150C (en) | Selective p2x3 modulators | |
ES2603262T3 (en) | Substituted aminoindane-carboxylic and aminotetralin-carboxylic acids and their use | |
EP2014653A1 (en) | Novel dicarboxylic acid derivatives as S1P1 receptor agonists | |
US5877191A (en) | Phenyl spiroethercycloalkyl tachykinin receptor antagonists | |
WO2006123725A1 (en) | Pyrrolidine derivative or salt thereof | |
JP2005531506A (en) | Aminoalkylphosphonates and related compounds as agonists of EDG receptors | |
EP2194044A1 (en) | Quinolone derivative | |
JP2008517897A (en) | Novel dicarboxylic acid derivatives | |
JP5296073B2 (en) | Benzoyl-piperidine derivatives as dual modulators of 5-HT2A and D3 receptors | |
TW201141856A (en) | (R)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, a partial agonist of 5-HT4 receptors | |
TW202304864A (en) | 1,3-substituted cyclobutyl derivatives and uses thereof | |
EP2697219B1 (en) | Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists | |
JP2011528346A (en) | Novel compounds active as muscarinic receptor antagonists | |
WO1992017440A1 (en) | Tricyclic compound | |
JP2006509793A (en) | Isophthalic acid derivatives | |
WO2005073183A1 (en) | Aryl sulfide derivative | |
WO2012065527A1 (en) | Compouds and uses as l-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof | |
CN110372571A (en) | A kind of 2- (2,2- diaryl ethyl)-Cycloamine derivative or salt and synthesis and application and composition | |
JP2023035972A (en) | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt | |
NZ617500B2 (en) | Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists | |
WO2014142056A1 (en) | Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof | |
WO1998017660A1 (en) | Phenyl spiroethercycloalkyl tachykinin receptor antagonists | |
JP2008001596A (en) | Sodium channel inhibitor | |
WO2005080385A1 (en) | Indanol derivative | |
EA046249B1 (en) | LOW MOLECULAR FXR AGONISTS, THEIR PRODUCTION METHOD AND APPLICATION |